

***ALX1*-related Frontonasal Dysplasia Results From Defective Neural Crest Cell Development and Migration**

Jonathan Pini^{1,2,*}, Janina Kueper^{1,2,3,*}, Yiyuan David Hu^{1,2}, Kenta Kawasaki^{1,2}, Pan Yeung^{1,2}, Casey Tsimbal^{1,2}, Baul Yoon⁴, Nikkola Carmichael⁵, Richard L. Maas⁵, Justin Cotney⁶, Yevgenya Grinblat⁴, and Eric C. Liao^{1,2,7}

¹ Center for Regenerative Medicine, Department of Surgery, Massachusetts General Hospital

² Shriners Hospital for Children, Boston

³ Life & Brain Center, University of Bonn

⁴ Departments of Integrative Biology, Neuroscience, and Genetics Ph.D. Training Program
University of Wisconsin-Madison

⁵ Department of Genetics, Brigham and Women's Hospital, Harvard Medical School

⁶ Genetics & Genome Sciences, UConn Health

*These authors contributed equally to this work

Short running title: Defective Neural Crest Cells Cause *ALX1*-related Frontonasal Dysplasia

⁷ Corresponding author

Eric C. Liao, MD, PhD

Director, Cleft and Craniofacial Center

Simches Research Building, CPZN4

185 Cambridge Street

Boston, MA 02114

ABSTRACT

A pedigree of subjects with frontonasal dysplasia (FND) presented with bilateral oblique facial clefts and ocular phenotypes. Genome sequencing and analysis identified a L165F missense variant in the homeodomain of the transcription factor *ALX1* which was imputed to be pathogenic. Induced pluripotent stem cells (iPSC) were derived from the subjects and differentiated to neural crest cells (NCC). NCC derived from *ALX1*^{L165F/L165F} iPSC were more sensitive to apoptosis, showed an elevated expression of several neural crest progenitor state markers, and exhibited impaired migration compared to wild type controls. NCC migration was also evaluated *in vivo* using lineage tracing in a zebrafish model, which revealed defective migration of the anterior NCC stream that contributes to the median portion of the anterior neurocranium, phenocopying the clinical presentation. Analysis of human NCC culture media revealed a change in the level of bone morphogenic proteins (BMP), with a low-level of BMP2 and a high level of BMP9. Soluble BMP2 and BMP9 antagonist treatments were able to rescue the defective migration phenotype. Taken together, these results demonstrate a mechanistic requirement of *ALX1* in NCC development and migration.

INTRODUCTION

The central part of the human face contains key anatomic features and sensory organs that enable us to interact with the environment and each other. The embryologic processes that form midface structures including the eyes, nose, upper lip and maxilla, are tightly regulated (Johnston, Minoux & Rijli, Rada-Iglesias, Prescott et al.). The midface structures form as the centrally located frontonasal prominence extends anteriorly, coalescing with elements derived from the paired maxillary prominences (Johnston, 1966, Le Lièvre, 1978, Le Lièvre & Le Douarin, 1975, Sadaghiani & Thiébaud, 1987). The embryonic facial prominences are derived from distinct migrating streams of cranial neural crest cells (NCC) that are conserved across vertebrates (Barrallo-Gimeno, Holzschuh et al., Chai, Jiang et al., Dougherty, Kamel et al., Le Douarin, Ziller et al., 1993, Olsson, Moury et al., Schilling, Walker et al., Trainor, Sobieszczuk et al., Wada, 2005). NCC migration and differentiation are highly coordinated and are associated with dynamic gene expression patterns (Simoës-Costa & Bronner, 2015). Key signaling pathways that regulate NCC development involve BMP, Wnt, FGF or Notch which activate the expression of transcription factors such as *PAX3*, *ZIC1*, *TFAP2a*, *MSX1/2* and *DLX5* (Khudyakov & Bronner-Fraser, 2009, Meulemans & Bronner-Fraser, 2002, Simoës-Costa & Bronner, 2015, Stuhlmiller & Garcia-Castro, 2012). Disruptions of NCC development contribute to a number of congenital malformations such as Waardenburg syndrome (WS), velocardiofacial syndrome / DiGeorge syndrome, Hirschsprung's Disease, congenital heart conditions, and craniofacial anomalies (Fox, Golden et al., Pierpont, Basson et al., 2007, Sedano, Cohen et al., Uz, Alanay et al., 2010)

Frontonasal dysplasia (FND) is considered a rare “orphan” disease (ORPHA250), with very few cases reported in the literature. The true prevalence of FND and the majority of its causes remain unknown. To date, six genetic causes of subtypes of FND with varying patterns of inheritance have been described in individual case reports: *EFNB1* (MIM 300035) in X-linked craniofrontonasal syndrome (MIM 304110); *ALX3* (MIM 606014) in FND type 1 (MIM 136760); *ALX4* (MIM 605420) in FND type 2 (MIM 613451); *ALX1* (MIM 601527) in FND type 3 (MIM 613456); *ZSWIM6* (MIM 615951) in dominant acromelic frontonasal dysostosis (MIM 603671); and *SPECC1L* (MIM 614140) in Teebi syndrome (MIM 145420)(Bhoj, Li et al., 2015, Kayserili, Uz et al., 2009, Smith, Hing et al., 2014, Twigg, Kan et al., 2004, Twigg, Versnel et al., 2009, Ullah, Kalsoom et al., 2016, Uz et al., 2010, Wieland, Jakubiczka et al., 2004). The heterogeneity of clinical phenotypes, including a wide range of possible ocular and craniofacial components, likely corresponds to different underlying genetic variants, genetic environments, and epigenetic modifications.

This study examined a pedigree of FND and identified a pathogenic variant in the homeodomain of transcription factor ALX1 resulting in a likely loss of function. A human stem cell model of FND was generated in order to investigate the effect of *ALX1* mutations on NCC behavior. Cellular and molecular characterizations identified a number of differences between subject-derived and control NCC that shed light on the developmental processes that are disrupted in FND. *In vivo* characterization of *alx1* in zebrafish revealed defective migration of the most anterior cranial NCC. This study underscores the utility of complementary human iPSC and zebrafish models to gain mechanistic insight into the molecular and cellular basis of *ALX1*-related FND.

RESULTS

Clinical features of ALX1-related FND in a Consanguineous Pedigree

A family with 4 children born of consanguineous parents of Amish heritage presented with complex FND. The FND phenotype was inherited in a Mendelian recessive fashion. Both parents, 1 unaffected sibling and 3 affected children (one male and two females) were consented and enrolled in the study (Figure 1A, subject numbers indicated in red). The parents (subjects 1 and 2) and 9 unaffected siblings (including subject 3) had normal facial structures without clinical stigmata suggestive of mild FND. All 4 affected children presented with bilateral oblique facial clefts, extending from either side of the nasal bone, involving both the primary and secondary palate. Among the affected children, there was some variability of the ocular phenotype, where the older affected girl (subject 4) presented with bilateral coloboma and asymmetric microphthalmia, whereas the 3 other affected children (including subjects 5 and 6) exhibited bilateral anophthalmia, with deficient upper and lower eyelids covering a shallow orbit. Subject 6 was the most severely affected and presented with bilateral oblique facial clefts and anophthalmia as well as no upper and lower eyelids, leaving the mucous membranes of both orbits exposed. Her nasal remnant also lacked the lateral alar subunits and is surrounded by several nodular skin tags.

Identification of pathogenic ALX1-variant

Whole exome sequencing (WES) was performed on blood samples collected from subjects 1-5, which corresponded to both parents, one unaffected sibling, and two affected children. A missense L165F variant (c.648C>T) was identified in the homeodomain of *ALX1*, which was heterozygous in the parents ($ALX1^{165L/165F}$), wildtype in the unaffected sibling ($ALX1^{165L/165L}$), and homozygous in both affected subjects ($ALX1^{165F/165F}$) (Figure 1B). WES results were confirmed by Sanger sequencing of the entire *ALX1* coding sequence. The *ALX1* L165F missense variant has not been reported in connection with an *ALX1*-related instance of FND in the literature, or been recorded as a variant in the gnomAD database (Karczewski K.J., 2019) (Figure 1C,D). The *ALX1* L165F amino acid substitution was predicted to be damaging and disease causing by *in silico* tools (Sift, Polyphen, muttaster, fathmm), and with haploinsufficiency consistent with the observed autosomal recessive inheritance pattern of this pedigree (Adzhubei, Schmidt et al., 2010, Lowe, 1999, Schwarz, Cooper et al., 2014, Shihab, Gough et al., 2014).

Generation of patient-derived iPSC model of ALX1-related FND

iPSC lines were generated using peripheral blood mononuclear cells (PBMC) obtained from whole blood samples that were collected from three unrelated wild-type individuals ($ALX1^{165L/165L}$), the heterozygous father ($ALX1^{165L/165F}$), and two of the four affected children

(Subjects 5 and 6; $ALX1^{165F/165F}$). PBMC were subsequently reprogrammed into iPSC (Supplemental Figure 1). Overall, 22 mutant $ALX1^{165F/165F}$ iPSC clones were successfully isolated and expanded from the two affected subjects, 13 $ALX1^{165L/165F}$ clones were isolated and expanded from the heterozygous father, and 35 $ALX1^{165L/165L}$ clones were isolated and expanded from healthy controls. Six $ALX1^{165F/165F}$ mutant clones (3 for each affected subject), 3 $ALX1^{165L/165F}$ clones from the heterozygous father, and 9 $ALX1^{165L/165L}$ clones from healthy controls (3 from each control) were fully characterized to confirm their pluripotency (Figure 1E) and ability to generate the three germ layers (Figure 1F). Sanger sequencing confirmed that the affected $ALX1^{165F/165F}$ and the heterozygous $ALX1^{165L/165F}$ -derived iPSC clones retained the $ALX1$ L165F genotype through reprogramming. Copy number variant analysis did not show any amplifications or deletions.

Generation and characterization of iPSC-derived NCC

Given the primary role of neural crest cells in midface morphogenesis, the iPSC clones were differentiated into NCC using a protocol adapted from a previous study (Pini, Giuliano et al., 2018) (Figure 2A). All NCC displayed similar morphological features and were indistinguishable at the colony level immediately following differentiation at passage 1 (Figure 2B).

Overexpression of neural plate border specifier genes in $ALX1^{165F/165F}$ NCC

A panel of marker genes at the center of the gene regulatory network required for NCC survival and differentiation was selected to be examined in detail across the 14 days of the neural crest differentiation protocol (Figure 3) (Barrallo-Gimeno, Holzschuh et al., 2004, Sauka-Spengler & Bronner-Fraser, 2008, Sauka-Spengler, Meulemans et al., 2007, Simoes-Costa & Bronner, 2015). The NCC gene expression results can broadly be divided into three groups. The first group includes genes that did not significantly differ between affected, heterozygous and unaffected controls. This group of genes comprises the neural crest specifiers *FOXD3* and *P75*, as well as the lineage specifier *HAND2*. The second group includes genes where the affected cells exhibited expression pattern that differed significantly from the heterozygous and the unaffected control cells, with no difference between the heterozygote and the control. This group of genes includes the neural plate border specifiers *ZIC1*, *PAX7*, *PAX3*, *MSX1*, and *DLX5*, as well as the neural crest specifiers *SNAI2* and *TWIST1* ($p < 0.05$ between days 2-8 when comparing subjects'-, father- and control NCC for *ZIC1*, *PAX7*, *DLX5*; $p < 0.05$ between days 2-14 when comparing subjects'-, father- and control NCC for *PAX3*, *MSX1*, *SNAI2*, and *TWIST1*). The final group includes genes that were significantly differentially expressed between the affected homozygous, heterozygous, and unaffected control cells. This group comprised the neural plate border

specifier *MSX2*, *DLX5*, and the neural crest specifier *TFAP2A* ($p < 0.05$ between days 2-14 when comparing subjects', father- and control NCC for *MSX2*, *DLX5* and *TFAP2A*). Of note, all significantly differentially expressed genes in the affected cells were overexpressed above the levels observed in the heterozygous and unaffected control cells, consistent with a putative role of *ALX1* as a transcriptional repressor.

ALX1 itself was found to be differentially expressed between affected cells when compared to the heterozygous and unaffected control cells at day 8 during NCC differentiation. The unaffected control and heterozygous cells exhibited similar *ALX1* expression levels, with peak expression level reached at day 8 where unaffected cells exhibited a plateaued, lower level of expression. The greatest difference in gene expression levels was observed early in the NCC differentiation process, around days 2-8 (such as in the cases of *ZIC1*, *PAX3*, *PAX7*, *DLX5*, and *TWIST1*). This characterization suggests an early function for *ALX1* in NCC differentiation, and identifies the 2-8 day window for in-depth transcriptome analysis in future studies.

Increased sensitivity to apoptosis in $ALX1^{165F/165F}$ NCC

Since anomalies in cell cycle progression predispose cells to apoptosis, and given the importance of apoptosis in regulating craniofacial development, the impact of the *ALX1*^{165F/165F} gene variant on the sensitivity of the iPSC-derived NCC to apoptosis was analyzed. Basal apoptosis levels, determined by the percentage of Annexin V positive cells, did not differ between control NCC ($4 \pm 0.2\%$) and *ALX1*^{165F/165F} NCC ($4.82 \pm 0.65\%$) (Figure 4A). After apoptosis induction via heat shock, the percentage of Annexin V positive cells significantly increased specifically in *ALX1*^{165F/165F} NCC ($87.97 \pm 2.44\%$) versus control NCC ($24.15 \pm 0.96\%$). These findings suggest that the affected subject's *ALX1*^{165F/165F} NCC are more sensitive to apoptosis.

These findings also indicate that *ALX1* functions in proliferating NCC. To determine if *ALX1* function is required for cell cycle progression, we investigated expression of Cyclin D1 (*CCND1*), required for the cell cycle G1/S transition, and Cyclin A2 (*CCNA2*), required for the DNA synthesis during the S-phase, were investigated. Both cyclins are expressed throughout the active cell cycle, from the G1/S transition to the G2/M transition (Minarikova, Benesova et al., 2016, Pagano, Pepperkok et al., 1992). Expression levels of *CCND1* and *CCNA2* were compared between control and *ALX1*^{165F/165F} NCC at passages 2 and 3 post-differentiation. The *ALX1*^{165F/165F} NCC were found to express significantly more *CCNA2* and *CCND1* at both passage 2 and passage 3 compared to the control NCC, consistent with a greater degree of active cellular proliferation (Figure 4B).

ALX1^{165F/165F} NCC do not undergo mesenchymal marker transition

As NCC clones derived from the control *ALX1^{165L/165L}*, heterozygous *ALX1^{165L/165F}*, and homozygous *ALX1^{165F/165F}* iPSC were maintained in culture, consistent qualitative morphologic differences were observed across cell passages. While control-derived NCC became progressively spindle-shaped and elongated, the mutant *ALX1^{165F/165F}* NCC remained rounded (Figure 2B). In order to investigate these differences more fully, flow cytometry was performed across different cell passage cycles in order to investigate the effect of the *in vitro* maturation of the NCC via an examination of NCC marker expression. At passage cycles 1-4, a number of key surface markers were examined. Expression of CD57 (synonym: HNK-1), indicative of NCC precursors before their commitment to downstream cell lineages (Minarcik & Golden, 2003), as well as markers of mesenchymal differentiation, CD105, CD73, and CD90, were assessed (Figure 4C).

Table 1 contains the precise percentage values of the FACS analysis of NCC at varying passage numbers. At passage 1 following differentiation, control and homozygous *ALX1^{165F/165F}* NCC expressed similar levels of neural crest precursor marker CD57. The control and homozygous *ALX1^{165F/165F}* NCC also expressed similar levels of mesenchymal markers CD90, CD105 and CD73. No significant differences were observed in marker expression between control and homozygous *ALX1^{165F/165F}* NCC at this stage ($p > 0.05$). However, by passage 4, control NCC exhibited decreased CD57 expression, and increased expression of CD90, CD105, and CD73, consistent with a progression to MSC differentiation. In contrast, homozygous *ALX1^{165F/165F}* NCC displayed a similar expression of the aforementioned NCC- and MSC markers at passage 4 as they did at passage 1 (Figure 4C).

The persistent CD57 expression in the homozygous *ALX1^{165F/165F}* NCC, taken together with the elevated expression of neural crest specifier genes *ZIC1*, *PAX7*, *PAX3*, *MSX1*, *MSX2*, and *DLX5*, suggest that the mutant NCC may be unable to progress from the progenitor to the differentiating state. To understand whether the persistent CD57 expression had an effect on the ability of the homozygous *ALX1^{165F/165F}* NCC to differentiate into downstream cell types, multi-lineage differentiation experiment was performed. Control and homozygous *ALX1^{165F/165F}* NCC demonstrated equal ability to differentiate into Schwann cells (GFAP and S100B positive expression), adipocytes (oil Red O. staining), chondrocytes (Alcian Blue, Safranin O. and Toluidine Blue staining), and osteoblasts (Alizarin Red S., Von Kossa staining and strong alkaline phosphatase activity) (Supplemental Figure 2). The maintenance of CD57 and lack of elevation of CD90 / CD105 / CD73 and the same ability to differentiate into NCCs derivatives suggest that the homozygous *ALX1^{165F/165F}* failed to progress through

the process of NCCs differentiation despite multiple cell passages and are blocked into the progenitor state.

Homozygous $ALX1^{165F/165F}$ NCC displays a migration defect

During embryonic development, NCC migrate to specific locations in order to form the prominences that coalesce to shape the face. To investigate the migratory properties of the iPSC-derived NCC *in vitro*, a wound healing assay with a central clearing was used. A significant migration defect was observed in the homozygous $ALX1^{165F/165F}$ NCC when compared with control NCC (Figure 5A, Film 1). Control NCC were able to migrate and fully cover the central clearing area of the wound healing assay after 24 hours (recovery of $95.99\pm 3.22\%$ of the surface area). In contrast, the homozygous $ALX1^{165F/165F}$ NCC covered less than half of the central clearing surface area ($38.79\pm 3.22\%$ for $ALX1^{165F/165F}$ NCC).

$ALX1^{165F/165F}$ NCC show differences in BMP secretion

The family of BMP family of growth factors play a critical role in NCC migration (Sato, Sasai et al., 2005, Tribulo, Aybar et al., 2003). This, in combination with the increased expression of *TWIST1* in $ALX1^{165F/165F}$ NCC, a known BMP inhibitor, led to us to hypothesize that $ALX1^{165F/165F}$ NCC might display abnormal levels of secreted BMP when compared to healthy control NCC (Hayashi, Nimura et al., 2007). To test this hypothesis, the levels of secreted BMP in the culture medium of $ALX1^{165F/165F}$ and control NCC were measured via multiplex analysis. The concentration of BMP2 was found to be significantly reduced in control $ALX1^{165F/165F}$ NCC (11.9 ± 0.65 pg/ml) compared to control NCC (19.52 ± 0.9 pg/ml) ($p < 0.05$) (Figure 5B). In contrast, the BMP9 concentration was significantly increased in mutant $ALX1^{165F/165F}$ NCC (3.72 ± 0.85 pg/ml) compared to control NCC (0.25 ± 0.02 pg/ml). BMP4, BMP7 and BMP10 levels were undetectable.

To follow-up on the observed dysregulation of BMPs, we hypothesized that treatments to counteract BMP2 reduction or BMP9 elevation could result in an improved migration phenotype. The $ALX1^{165F/165F}$ NCC were treated with different concentrations of soluble BMP2, the BMP9 antagonist Crossveinless (CV2), or a combination of the two (Figure 5C, Supplemental Figure 3, Film 2, Supplemental Film 1). Treatment with an increasing concentration of BMP2 from 10ng/ml to 50ng/ml was able to restore the migration of homozygous $ALX1^{165F/165F}$ NCC in a dose dependent manner. However, no difference was observed between 50ng/ml and 100ng/ml of BMP2, suggesting a saturation effect ($64.53\pm 3.17\%$ for 50ng/ml BMP2, and $67.31\pm 3.25\%$ for 100ng/ml BMP2).

Likewise, treatment with the BMP9 antagonist CV2 was able to partially rescue the migration defect of homozygous $ALX1^{165F/165F}$ NCC. The low dose of 10ng/ml of CV2 did not show a significant effect on the migration defect of treated and untreated $ALX1^{165F/165F}$ NCC ($37.5\pm 2.5\%$ for 10ng/ml CV2). As observed with BMP2, treatments with both 50ng/ml and 100ng/ml of CV2 were able to partially restore the ability of the homozygous $ALX1^{165F/165F}$ NCC to migrate, with no difference found between these two concentrations ($57.6\pm 4.77\%$ for 50ng/ml of CV2, and $64.64\pm 3.36\%$ for 100ng/ml of CV2). Finally, we asked if treatment with a combination of BMP2 and CV2 would exert an additive or synergistic effect to restore cell migration than single compound treatment. No additive effect was identified, as BMP2 and CV2 co-treatment at 100ng/ml was able to rescue the migration defect phenotype of mutant $ALX1^{165F/165F}$ NCC at a similar level to what was observed with the individual treatments ($73\pm 5.89\%$ for BMP2 and CV2 co-treatment).

Evaluation of alx1 function in the zebrafish

We and others previously showed that the zebrafish anterior neurocranium (ANC) forms from the convergence of the frontonasal prominence and the paired maxillary prominences (Dougherty, Kamel et al., 2012, Eberhart, 2006, Wada, 2005). Since FND malformation is characterized by facial cleft affecting fusion of the frontonasal and maxillary structures, examination of the ANC morphology in zebrafish would be a sensitive assay for frontonasal development.

To generate an in vivo model of *alx1*, we employed CRISPR/Cas9-mediated targeted mutagenesis of the *alx1* locus in zebrafish. This approach produced a frame-shift mutation harboring a 16-base pair (bp) deletion in exon 2 of *alx1* (NM_001045074), named $alx1^{uw2016}$ (Figure 6A, Supplemental Figure 4). The $alx1^{uw2016}$ mutation is likely to cause complete loss of function, since the encoded truncated protein lacks both the homeobox- and transactivation domains. While the majority of $alx1^{uw2016}$ homozygous zebrafish developed normally and were viable as adults, approximately 5% displayed specific craniofacial defects (Supplemental Figure 5). Alcian blue staining of $alx1^{uw2016}$ homozygous larvae at 5 days post fertilization (dpf) revealed that the posterior neurocranium and ventral cartilages as well as the Meckel's cartilage were formed but smaller in size in a subset of zebrafish. In contrast, the ANC appeared dysmorphic, i.e. narrower in the transverse dimension and linear, rather than fan-shaped (Figure 6A). The chondrocytes of the ANC appeared cuboidal in mutant larvae, whereas wildtype ANC chondrocytes were lenticular and stacked in an intercalated pattern (Figure 6A).

The low penetrance of the ANC defect suggests the possibility of gene compensation by other *alx* family members (also see Discussion). To test this hypothesis, *alx* transcripts were quantified by qRT-PCR at several stages of embryogenesis in *alx1^{uw2016}* homozygotes. We observed that *alx1* mRNA level was significantly decreased in *alx1^{uw2016}* mutants across several time points, likely because the mutation triggers nonsense-mediated decay (Figure 6B) (El-Brolosy, Kontarakis et al., 2019). Consistent with transcriptional gene compensation, *alx3* and *alx4a* mRNA levels were significantly increased in the *alx1^{uw2016}* mutant embryos compared to wild type embryos ($p < 0.05$ for 10ss, 24hpf and 36hpf embryos for *alx3*; $p < 0.05$ for 24hpf and 36hpf embryos for *alx4a*). These data suggest that *alx3* and *alx4a* functions may compensate for the loss of *alx1* during zebrafish development (Figure 6B).

Given the likely genetic compensation between different *alx* family members, we utilized a dominant negative approach to interrogate the function of *alx* genes in embryonic development. It has been reported that ALX1 protein homodimerizes to be fully functional (Furukawa, Iioka et al., 2002). In order to circumvent the genetic compensation by *alx3*, and *alx4a*, a truncated form of *alx1* containing the N-terminal domain (Alx1DN) was generated. The Alx1DN truncation contains the DNA binding homeodomain but is missing the transactivation domain (Herskowitz, 1987). Additionally, an alternative truncated protein that lacks the DNA binding homeodomain and contains the transactivation domain, termed Alx1CT, was generated. We reasoned that, if a truncated Alx1 protein can occupy its binding sites but fail to dimerize or associate with its coactivators, it may function in a dominant negative manner.

When Alx1DN was over-expressed by mRNA injection in wild-type zebrafish embryos, embryos displayed significant craniofacial defects (Figure 6C), while Alx1CT-expressing embryos developed normally. On closer inspection with Alcian blue staining, Alx1DN-expressing embryos showed complete abrogation of the frontonasal-derived median section of the ANC and the Meckel's cartilage, a similar but more severe phenotype as expected due to the interference with all *alx* proteins than that observed in *alx1^{uw2016}* mutant embryos. Both *alx1^{uw2016}* and the Alx1DN mutant phenotypes suggest that *alx1* regulates the migration of the anterior frontonasal NCC stream that contributes to the median portion of the ANC.

Lineage tracing reveals migration defect of NCC

To elucidate whether anterior cranial NCC migration is specifically affected in Alx1DN embryos, lineage tracing of the migrating NCC was carried out using the *Tg(sox10:kaede)* reporter line (Dougherty et al., 2012, Eberhart, 2006, McGurk, Lovely et al., 2014, Wada, Javidan et al., 2005). The anteromost stream of NCC in wild type and Alx1DN injected

embryos was labeled at the 10-somites stage and followed to 96 hours post-fertilization (Figure 6D). In the wild-type embryos, at 4 days post-fertilization (dpf), the NCC were able to migrate into the frontonasal region of the palate (Figure 6D). In contrast, the anterior cranial NCC of Alx1DN injected embryos were unable to reach their final location of the median ANC. Instead, the NCC in the Alx1DN injected zebrafish were found in an ectopic anterior location outside of the frontonasal domain (Figure 6D, Film 3). While it is possible that increased cell death and altered cell division that were observed in the iPSC model are also operating here in the embryo, these cellular derangements are likely minor contributors to explain the ectopic localization of the cranial NCC, whereas altered cell migration is the dominant mechanism.

DISCUSSION

We report the identification of a novel missense variant of human *ALX1* associated with FND. Analysis of this putative loss-of-function variant in patient-derived iPSC and NCC showed a lack of cellular maturation, an increase in apoptosis, and a migration defect. We identified an overexpression of neural plate border specifiers in subject-derived cells, and an imbalance of BMP levels which, when addressed, was capable of mitigating the migration defect discovered in the subject's NCC. A delay of NCC migration was also recognized as key to the morphologic consequences of a loss of *alx1* in zebrafish models. We could identify genetic compensation between different members of the *alx* gene family.

Human genetics of ALX1

Genes of the *ALX* family encode homeodomain transcription factors and are associated with craniofacial malformations. Like other members of this family, the *ALX1* protein is composed of two main functional domains: the N-terminal portion containing the DNA binding homeodomain with two nuclear localization signals, and the C-terminal portion containing an OAR/aristaless domain required for transactivation and protein interaction (Furukawa et al., 2002). In this study's pedigree, a novel missense variant L165F within the conserved homeodomain was identified. Leucine is an aliphatic, branched amino acid whilst Phenylalanine is an aromatic, neutral and nonpolar amino acid. Due to properties of Leucine, the substitution itself is likely disruptive to helix II in the DNA-binding element of the homeodomain within which it resides. Disruptive Leucine to Phenylalanine substitutions have been described in a number of published, genotyped disorders (Gomez & Gammack, 1995, Miller, Lyle et al., 1992). Pathogenic missense variants within the homeodomains of both *ALX3* and *ALX4* have previously been identified as the causes of FND types 1 and 2, respectively (Twigg et al., 2009, Wuyts, Cleiren et al., 2000).

Pathogenic *ALX1* gene variants in FND have been reported in two case studies in the literature. The first study described two families (Uz et al., 2010). In the first, three siblings of consanguineous parents were described to suffer from a midline defect of the cranium, bilateral extreme microphthalmia, bilateral oblique cleft lip and palate, a caudal appendage in the sacral region, and agenesis of the corpus callosum. A homozygous 3.7 Mb deletion spanning *ALX1* was identified in all affected subjects. In a second family, one affected subject was born with a midline defect of the cranium, bilateral microphthalmiamicrophthalmia, bilateral oblique cleft lip and palate, and a thin corpus callosum. A donor-splice-site mutation c.531G>A of *ALX1*, homozygous in the child and heterozygous in the parents, was identified to be the likely cause of the child's phenotype.

None of the affected subjects from the pedigree reported in this study demonstrated midline defects of the cranium or a cerebral phenotype. This is in spite of the fact that the missense mutation of the affected subjects in our study lies just proximal to that of family 2, within helix II, within the homeodomain.

A second case report described one family with FND (Ullah et al., 2016). It reported on four children born of consanguineous parents that presented with a broad nasal root, smooth philtrum, and mouth protrusion. An *ALX1* gene variant c.661-1G >C was found to be heterozygous in the parents and homozygous in the affected children. The skipping of the exon via alternative splicing likely resulted in a mutant protein with some residual function, explaining the relatively mild phenotype.

The ALX gene family: ALX1, ALX3, and ALX4

The *ALX* gene family consists of three members: *ALX1*, *ALX3* and *ALX4* (McGonnell, Graham et al., 2011). In humans, mutations of each *ALX* gene have been associated with craniofacial malformations of the frontonasal derived structures with variable phenotypic severity (Mavrogiannis, Antonopoulou et al., 2001, Twigg et al., 2009, Uz et al., 2010, Wu, Badano et al., 2000, Wuyts et al., 2000). FND is a descriptive term that broadly describes a number of malformations of the midface. Previously classified based on appearance (see Tessier, Sedano, De Myer classifications), FND related to variants within the *ALX* gene family has recently been reordered on the basis of genetics: type I is caused by mutations of *ALX3*; type 2 is caused by mutations of *ALX4*; and type 3 is caused by mutations of *ALX1*. FND types 1 and 2 appear milder than type 3, frequently presenting with altered appearance of the nasal soft tissue (Twigg et al., 2009).

In mouse and zebrafish, *Alx1*, *Alx3*, and *Alx4* have been shown to be expressed in spatiotemporally restricted regions of the craniofacial mesenchyme (Beverdam & Meijlink, 2001, Dee, Szymoniuk et al., 2013a, Lours-Calet, Alvares et al., 2014, Qu, Li et al., 1997, ten Berge, Brouwer et al., 1998, Zhao, Eberspaecher et al., 1994). Evidence of gene compensation has previously been reported in animal studies (Beverdam, Brouwer et al., 2001, Dee et al., 2013a). In studies of sea urchins, *Alx4* was shown to be directly regulated by *Alx1* (Rafiq et al., 2014; Khor et al, 2019). The question remains how the different *ALX* family members regulate craniofacial development, through transcriptional activation or repression of shared and unique target genes.

iPSC-derived NCC for craniofacial disease modeling

Most craniofacial structures are derived from a transient multipotent embryonic population called NCC. The NCC progenitors give rise to a wide variety of cell lineages including peripheral neurons, melanocytes, as well as craniofacial mesenchyme (Betancur, Bronner-Fraser et al., 2010, Stuhlmiller & Garcia-Castro, 2012). NCC exhibit a restricted expression of *ALX1* in the rostral domain during early developmental stages (Dee et al., 2013a, Zhao, Behringer et al., 1996a). Cellular and genetic mechanisms that drive frontonasal NCC formation are poorly understood. In order to gain insight into the functional consequences of the clinically pathogenic *ALX1* gene variant identified in this study's pedigree, iPSC were differentiated into NCC.

While a number of sophisticated protocols using chemically defined mediums and a combination of adherent and/or suspension culturing approaches have been published in recent years, no consensus has been established on a number of controversial issues (Bajpai, Chen et al., 2010, Leung, Murdoch et al., 2016, Tchieu, Zimmer et al., 2017). First, the definition of what a NCC in fact is remains based entirely on the transcriptomic profiling performed in animal studies. Whilst we succeeded in identifying distinctive differences between the *ALX1*^{165F/165F} NCC and healthy controls, the results suffer from an obvious limitation: a lack of understanding which stage of development the NCC represent. The central challenge of the work with iPSC models of human disease remains the lack of available human transcriptomic cell data to allow for an understanding which stage of development is modeled by the cellular lineages derived. NCC are characterized *in vitro* by the expression of markers identified to be specific to this cell population, namely P75, CD57, CD90, CD73 and CD105 (Billon, Iannarelli et al., 2007, Kawano, Toriumi et al., 2017, Minarcik & Golden, 2003) as well as their multi-lineage differentiation ability. NCC formation is a stepwise process coordinated by a spatiotemporally specific gene expression pattern. In this study, a putative loss of *ALX1* function did not impair NCC differentiation itself or the ability of NCC to differentiate into multiple cell lineages. Rather, it appeared that the clinically pathogenic *ALX1*^{165F/165F} variant maintained the NCC in a precursor state. While control cells progressively became craniofacial mesenchymal cells by CD57 down-regulation and increases in MSC associated marker expression, *ALX1*^{165F/165F} NCC did not undergo changes of their morphology or show a transition of progenitor to mesenchymal markers. Second, a lack of a 3D representation of NCC migration *in vitro* based studies force scientists to either transplant human iPSC-derived NCC into model organisms, or retain a 2D system of representation (Bajpai et al., 2010, Okuno, Renault Mihara et al.). We focused on the validation of the findings in human iPSC in zebrafish. Third, the development of craniofacial mesenchyme is a product of the interactions of derivatives of all three germ layers. This left the role of *ALX1* in other developmental derivatives unexplored in this study.

To allow for some insight into the expression profile of key NCC markers during the *in vitro* differentiation process, we surveyed relative expression via qPCR every 2 days throughout our differentiation protocol. We found the greatest differences between the unaffected father and the affected children in the expression of *PAX7*, *PAX3*, *DLX5*, *SNAI2*, and *TWIST1*. *ALX1* has been described as a transcription modulator capable of both activating and repressing target gene expression, adapting its activity to different cell types and environments (Cai, 1998, Damle & Davidson, 2011, Gordon, Wagner et al., 1996). Its activity as a repressor, for example, has been documented with prolactin, as *ALX1* binds directly to the prolactin promoter (Gordon et al., 1996). In this study, all of the genes were substantially upregulated in the affected children, with the greatest changes found in the earlier time points of differentiation. *ALX1* appears to play the role of a transcriptional repressor in NCC-based craniofacial development.

NCC delamination and migration depend on signals from the surrounding epidermis, including BMPs, which induce expression of neural plate border specifier genes such as *PAX3*, *TFAP2a*, *MSX1/2* or *ZIC1* (Dougherty, Kamel et al., 2013, Garnett, Square et al., 2012, Sato et al., 2005, Simoes-Costa & Bronner, 2015, Tribulo et al., 2003). Fine temporospatial regulation of the level of these signaling molecules is critical to allow for delamination and migration of NCC craniofacial development. BMPs belong to the transforming growth factor beta (TGF β) superfamily, and can be divided into several subcategories based on molecular similarities. The two BMPs showing dysregulation in this study, BMP2 and BMP9, belong to different subcategories which exhibit different expression patterns and receptors. BMP2 was identified as an important factor in migratory NCC development, with a depletion of mobile NCC in knockout models in transgenic mice resulting in hypomorphic branchial arches. (Kanzler, Foreman et al., 2000). In a complementary mouse model, BMP2 increased migration of NCC when added as a supplement to culture medium (Anderson, Stottmann et al., 2006). BMP2 was also found to be required for the migration of NCC in the enteric nervous system in the zebrafish, and to be significantly decreased in the gut of patients affected by Hirschsprung's disease, a disease characterized by deficient enteric NCC migration (Huang, Wang et al., 2019a). BMP9 on the other hand was shown to be required for tooth development in mice (Huang, Wang et al., 2019b). It was previously identified as a potent inducing factor of osteogenesis, chondrogenesis, and adipogenesis during development (Lamplot, Qin et al., 2013, Luther, Wagner et al., 2011). Opposed to other BMPs, including BMP2, BMP9 was found to be resistant to feedback inhibition by BMP3 and noggin (Wang, Hong et al., 2013).

The relationship of BMP2 and BMP9 in NCC development, migration, and differentiation has yet to be examined. Why BMP2 and BMP9 appeared to play antagonistic roles in the NCC modeling of *ALX1*-related FND presented in this study remains unclear. On the basis of the qPCR data and the multiplex assay revealing a decrease in BMP2 and an increase in BMP9 in NCC supernatant, we hypothesized that a lack of fully functional *ALX1* may account for the overexpression of neural plate border specifiers, and the change of BMP signaling. In substituting or repressing BMP2 and BMP9 respectively, an almost complete rescue of the migration defect of the mutant *ALX1*^{165F/165F} NCC was achieved. Pretreatment of subject-derived NCC could perhaps result in a complete rescue of migration.

Animal models of ALX1-related FND

Studies in sea urchins have contributed meaningful knowledge to the regulatory functions of *Alx1* as a transcription factor. In the sea urchin *S. purpuratus*, the *alx1* gene was found to activate itself in a self-regulatory loop at lower levels. Once its level exceeds a certain threshold, *alx1* reverses its activity and becomes a repressor of its own transcription (Damle & Davidson, 2011). As a transcription factor, *alx1* was found to be essential for the regulation of epithelial-mesenchymal transition, a process of great importance for the ability of NCC to delaminate and initiate migration (Ettensohn, Illies et al., 2003).

The specific role of *Alx1* in craniofacial development was investigated in different animal models. Targeted gene ablation of *Alx1* in mice resulted in neural tube closure defects in the majority of the pups, a phenotype not observed in any reported case report of *ALX1*-related FND type 3 (Zhao, Behringer et al., 1996b). A previously published morpholino knockdown of *alx1* in zebrafish suggested that the gene is essential for the migration of NCC into the frontonasal prominence, with a disorganization of NCC in the frontonasal stream, and reduction both in the number of NCC and its cellular projections (Dee, Szymoniuk et al., 2013b). A major weakness of morpholino gene disruption is non-specific or off target effects. This study utilized germline *alx1* mutant allele to investigate the effect of *alx1* loss-of-function, complemented by a dominant negative disruption approach to address gene compensation of other *alx* family members. These approaches corroborate a requirement for *alx1* in median ANC morphogenesis, corresponding to formation of the midface in humans.

Conclusion

In summary, this work describes a novel *ALX1* gene variant associated with FND. Using complementary human iPSC and zebrafish models, this study showed that *ALX1* is required for coordinated NCC differentiation and migration. Discordance of NCC differentiation from cell migration during midface morphogenesis results in FND. Future work will be directed at

identifying *ALX1* downstream targets and characterize the ALX regulated pathways in craniofacial development.

MATERIAL AND METHODS

Approvals to perform research with human samples and zebrafish

The collection of human blood and discard specimens, genome sequencing and generation of iPSC were approved by the Institutional Review Board of Partners Healthcare (IRB No. 2015P000904). Informed consent was obtained from the parents of the patients prior to all sample collections. All experimental protocols using zebrafish were approved by the Animal Care and Use Committees of Massachusetts General Hospital (IACUC No. 2010N000106) and the University of Wisconsin, and carried out in accordance with institutional animal care protocols.

iPSC and EB generation

PBMC were isolated using whole blood from two individuals (subjects 5 and 6: $ALX1^{165F/165F}$), the unaffected father (subject 1: $ALX1^{165L/165F}$), and three unrelated healthy individuals (controls: $ALX1^{165L/165L}$). Samples were diluted in an equal volume of PBS and gently transferred to a tube containing 4 ml of FICOLL. After centrifuging the sample for 10 minutes at 350 G, the FICOLL-plasma interface containing the PBMCs was recovered and washed several times in PBS. After 24 hours of recovery in StemPro-34 SFM medium (Invitrogen) supplemented with 100 ng/ml Stem Cell Factor (SCF, PeproTech, Rocky Hill, NJ), 100 ng/ml Fms-related tyrosine kinase 3 ligand (Flt3L, PeproTech), 20 ng/ml Interleukin-3 (IL-3, Peprotech) and 20 ng/ml IL-6 (Peprotech), 1 million PBMC were processed using the CytoTune-iPS 2.0 Sendai Reprogramming Kit (Invitrogen, Carlsbad, CA), following manufacturers instruction, for iPSC generation. 1 million PBMCs were infected with 3 different Sendai Viruses containing the Yamanaka reprogramming factors, *OCT4*, *SOX2*, *KLF4*, and *c-MYC*, in StemPro-34 SFM medium supplemented with cytokines. Starting on day 21, individual iPSC clones were picked based on morphologic criteria. Subsequently, the iPSC were maintained in StemFlex medium and passaged 1-2 a week using ReLSR (STEMCELL Technologies, Vancouver, BC, Canada) dissociation buffer. Since iPSC can exhibit genetic instability after reprogramming, the clones were expanded up to passage 10 before characterizing each cell line. The genetic stability of the cells was assessed analyzing copy number variants. Epigenetic differences were controlled for in a limited manner by ensuring that all major experiments were performed in both biologic- and technical triplicate at the identical passage number.

To form embryoid bodies (EB), iPSC were harvested using ReLSR dissociation buffer and clumps were transferred to a low adherent 6 well plate in differentiation medium containing 80% DMEM-F12, 20% Knock out Serum Replacer (Invitrogen), 1 mM non-essential amino acids, 1 mM Penicillin/Streptomycin, and 100 μ M 2-mercapthoethanol. The medium was

changed daily. After 14 days of differentiation, cells were recovered for RNA extraction and subsequent qPCR analysis of markers of the ectoderm, endoderm, and mesoderm.

Derivation of NCC and multi-lineage differentiation

In order to derive NCC, a previously published protocol for mesenchymal differentiation was adapted (Pini et al., 2018). iPSC medium was replaced by NCC-inducing medium containing DMEM-F12, 10% fetal bovine serum (FBS), 1 mM sodium pyruvate, 1 mM Penicillin/Streptomycin, 1 mM non-essential amino acid, 110 μ M 2-mercaptoethanol and 10 ng/mL Epidermal Growth Factor (EGF). The medium was changed every two days. After one week, cells were recovered using 0.25% trypsin-EDTA and transferred to new cultureware for an additional week. Following this, cells were harvested, phenotypically characterized by flow cytometry for their expression of NCC markers and assayed for their mesenchymal differentiation ability.

Schwann cell differentiation was performed as previously described (Kawano et al., 2017). NCC were plated on glass coverslips in 24-well tissue culture plates (0.2×10^5 cells per well) in neuronal differentiation medium consisting of a 3:1 ratio of DMEM-F12 and neurobasal medium supplemented with 0.25x B-27, 1mM glutamine, 1 mM Penicillin/Streptomycin for 5 weeks. The medium was changed weekly. At the end of the differentiation, cells were fixed in 4% formaldehyde and analyzed by immunohistochemistry for S100B (ThermoFisher, Waltham, MA) and GFAP expression (Abcam, Cambridge, United Kingdom).

Adipocyte and chondrocyte differentiation was performed as previously described (Pini et al., 2018). Adipogenesis was investigated using the StemPro adipogenesis differentiation kit (Life Technologies, Carlsbad, CA). NCC were seeded at 5×10^4 per well, in a 24-well plate, and cultured for 2 weeks, in complete adipogenesis differentiation medium. Lipid deposits were observed following staining with Oil Red O (MilliporeSigma, St. Louis, MO), according to manufacturer's instructions. After washing, cells were counterstained with Mayer's hematoxylin.

Chondrogenic differentiation was performed using the StemPro chondrogenesis differentiation kit (Life Technologies). NCC were seeded in a 12-well plate, in aggregates containing 8×10^4 cells, in 5 μ L of NCC medium, and placed in a 37°C, 5% CO₂ incubator for one hour. Following this, the NCC medium was replaced by chondrogenesis differentiation medium, and cultured for 20 days. The medium was changed once a week. Chondrogenic matrix formation was observed following Alcian blue, Safranin O and Toluidine Blue staining.

Osteoblast differentiation was performed using the StemPro osteogenesis differentiation kit (Life Technologies). NCC were plated in 12-well tissue culture plates (5×10^5 cells per well) in osteogenesis differentiation medium for 14 days. At the end of the differentiation, the

presence of mineralized nodules was assessed using Alizarin Red S, Von Kossa (silver nitrate) and Alkaline Phosphatase staining.

Images were acquired using the RETIGA OEM fast camera and Qcapture software (Teledyne QImaging, Surrey, BC, Canada).

Genomic DNA extraction and sequencing

Genomic DNA was extracted with the REExtract-N-Amp tissue PCR kit (MilliporeSigma), following the manufacturer's instructions. Sanger sequencing of *ALX1* to ensure *ALX1* sequence integrity in all iPSCs clones was carried out as previously described (Umm-e-Kalsoom, Basit et al., 2012). The four *ALX1* exons encoding the open reading frame were amplified using the CloneAmp HiFi PCR premix (Takara Bio Inc., Kusatsu, Shiga, Japan) and exon specific *ALX1* oligonucleotides. All exon specific PCR products were purified using the Qiaquick PCR purification kit (Qiagen, Hilden, Germany) prior to sequencing.

Whole-exome sequencing and analysis

Whole-exome sequencing (WES) of the affected subjects 3 and 4, an unaffected sibling and the parents was performed and analyzed assuming a recessive mode of inheritance given the presence of multiple affected siblings. Three compound heterozygous variants and one homozygous recessive variant were identified in the affected siblings (*ALX1* c.648C>T (p.L165F). This variant was predicted to be causative of the phenotype based on known gene function, the previously identified role of *ALX1* in frontonasal development, and the effect of the variant (substitution of phenylalanine for the highly conserved leucine in a DNA binding domain). Polymorphism Phenotyping v2, Sorting Intolerant from Tolerant, MutationTaster, and Functional Analysis through Hidden Markov Models (v2.3) were used for functional variant consequence prediction (Adzhubei et al., 2010, Lowe, 1999, Schwarz et al., 2014, Shihab et al., 2014). The gnomAD platform was used to identify any other missense variants at the location identified in the subjects (Karczewski K.J., 2019). Clustal Omega was used for multiple sequence alignment (Sievers, Wilm et al., 2011). Domain Graph was used to create the annotated schematic diagrams of *ALX1* and *ALX1* (Ren, Wen et al., 2009).

RNA extraction and processing

RNA was isolated using the RNAeasy Plus mini kit (Qiagen), following the manufacturer's recommendations. 1 µg of RNA was reverse transcribed using the SuperScript III first-strand synthesis system (ThermoFisher). All PCR reactions on cDNA were performed using the GoTaq DNA polymerase (Promega, Madison, WI) unless otherwise noted. For zebrafish RNA extraction, 24hpf Tübingen zebrafish embryos were harvested and homogenized using

a micropestle in TRIzol reagent (ThermoFisher), following manufacturer's instructions. Total RNA was then purified using phenol-chloroform. 1 µg of total RNA was reverse transcribed using the SuperScript III First-Strand Synthesis Kit (ThermoFisher), following manufacturer's recommendations.

Flow cytometry analysis

NCC were harvested and suspended in FACS buffer solution consisting of PBS with Ca²⁺ and Mg²⁺, 0.1% Bovine Serum Albumin (BSA), and 0.1% Sodium Azide. Approximately 2x10⁵ cells were incubated with the desired cell surface marker antibodies or isotype controls at 4°C for 15 min. Specific antibodies for CD90, CD73, CD105 and CD57 (BD Biosciences, San Jose, CA), and isotype control immunoglobulin IgG1 (BD Biosciences) were used for labelling. Antibodies were diluted in FACS buffer. After 3 washes in FACS buffer, samples were fixed in 0.4% formaldehyde, and processed using an LSR II flow cytometer (BD Biosciences). The data acquired was analyzed using FlowJo software (FlowJo, LLC).

Immunohistochemical analysis of iPSC

Cells were fixed with 4% formaldehyde in PBS for 15 min at room temperature, permeabilized with 1% saponin in PBS, and blocked using 3% BSA in PBS for 30 min at room temperature. The cells were then incubated with the primary antibodies for 3 hours at room temperature. The following primary antibodies and dilutions were used: rabbit anti-OCT4 (1:100, Life Technologies), mouse anti-SSEA4 (1:100, Life Technologies); rat anti-SOX2 (1:100, Life Technologies), mouse anti-TRA-1-60 (1:100, Life Technologies), rabbit anti-GFAP (1:500, Abcam) and rabbit-anti S100B (1:500, ThermoFisher). The cells were then incubated with the secondary antibodies for 1 hour at room temperature, washed with PBS and counterstained with DAPI (MilliporeSigma). Secondary antibodies were Alexa 594 donkey anti-rabbit, Alexa 488 goat anti-mouse, and Alexa 488 donkey anti-rat and Alexa 594 goat anti-mouse (ThermoFisher). Images were acquired using the RETIGA OEM fast camera and Qcapture software (Teledyne QImaging).

Staining of iPSC and mesenchymal NCC derivatives

Alkaline phosphatase activity was measured using the leukocyte alkaline phosphatase staining kit (MilliporeSigma), following the manufacturer instructions. Cells were first fixed using a citrate/acetone/formaldehyde solution for 30 seconds, washed several times, and stained with Fast Blue for 30 minutes. After further washing, these cells were counter stained with Mayer's hematoxylin. Alizarin Red S., Von Kossa, Alcian Blue and Toluidine Blue staining were performed as previously described (Pini et al., 2018). Cells were first fixed in 4% formaldehyde at room temperature for 15 minutes. Following a wash, cells were

incubated in either 1% Alizarin Red, 1% Silver nitrate, 0.1% Toluidine Blue, 0.02% Alcian Blue, or 0.1% Safranin O solution. For Von Kossa staining, cells were exposed to UV light until dark staining appeared. Images were acquired using the RETIGA OEM fast camera and Qcapture software (Teledyne QImaging).

Quantitative and non-quantitative polymerase chain reaction

Real-time PCR assays were conducted on a StepOnePlus real-time PCR system, using PowerUp SYBR Green Master Mix (Applied Biosystems, Waltham, MA). Transcript expression levels were evaluated using a comparative CT process ($\Delta\Delta CT$) with human *RPLP0* and *GAPDH* used as reference genes. For zebrafish, *elfa* and *18S* were used as reference genes. Specific primers were used for amplification as noted (Supplemental Table 1).

Apoptosis assay

2×10^5 cells were incubated for 30 min in the dark in 1x Fixable Viability Dye (FVD, Invitrogen) solution. After two washes in FACS buffer and one wash in binding buffer, cells were incubated 10-15 min in 1x Annexin V (BioLegend, San Diego, CA) solution in binding buffer composed by 0.1M HEPES (pH 7.4), 1.4M NaCl and 25mM CaCl₂. After one wash in binding buffer, cells were suspended in 200 μ l of binding buffer and immediately proceed using an LSR II flow cytometer (BD Biosciences) and analyzed using FlowJo software (FlowJo LLC, Ashland, OR). Apoptosis was induced by placing the cell suspension in a water bath at 55°C for 10 min.

Wound healing assay and analysis

Migration was investigated using the Radius™ 48-Well Cell Migration Assay (Cell Biolabs, Inc., San Diego, CA), following manufacturer's instructions. Control or *ALX1*^{165F/165F} NCC ($1 \times 10^5/w$) were plated in a 48-well plate containing a Radium™ Gel spot. Before beginning the migration assay, cells were washed 3 times with medium and incubated with gel removal solution for 30min at 37°C. Following three subsequent washes in medium, the NCC were placed in a culture chamber for live cell imaging at 37°C and 5% CO₂. Rescue experiments were performed through the addition of soluble BMP2, CV2 or a combination of the two at a concentration of 10, 50 or 100ng/ml to the medium at the beginning of the assay. For fluorescent pictures, cells were stained in serum free media containing 3.6 μ M CellTracker Green CMFDA (Life Technologies) for 30 min at 37°C and allowed to recover for 30 min before starting the experiment. All images were acquired using a Keyence BZ-X800 microscope. The time-lapse film was made by acquiring images every 15 min for 24 hours.

The fluorescent images were acquired every 6 hours. Surface area analyses and percentages of recovery were measured using ImageJ software (NIH, Bethesda, MD).

Multiplex analysis of BMP concentration

The concentration of the BMP family in the supernatant of *ALX1*^{165F/165F} NCC was measured using a bead-based multiplex array (Forsyth Institute, Cambridge, MA). Manufacturers' protocols were followed for all panels. Reagents were prepared as per kit instructions. Assay plates (96-well) were loaded with assay buffer, standards, supernatant from the *ALX1*^{165F/165F} NCC, and beads and then covered and incubated on plate shaker (500 rpm) overnight at 4°C. After primary incubation, plates were washed twice and then detection antibody cocktail was added to all wells; the plates were covered and left to incubate at room temperature for 1 hour on plate shaker. After the incubation, streptavidin-phycoerythrin fluorescent reporter was added to all wells, and the plate was covered and incubated for 30 minutes at room temperature on plate shaker. Plates were then washed twice and beads were resuspended in sheath fluid, placed on shaker for 5 minutes, and then read on a Bio-Plex®200 following manufacturers' specifications and analyzed using Bio-Plex Manager software v6.0 (Bio-Rad, Hercules, CA).

Plasmid construct generation

The In-Fusion Cloning Kit (Takara) and the In-Fusion Cloning primer design tool were used for primer design. Tübingen zebrafish *alx1* was amplified via PCR. Zebrafish *alx1* as cloned into the SpeI and PaeI (NEB, Ipswich, MA) restriction sites of pCS2+8 (Promega). The subsequent reaction product was used to transform One Shot TOP10 competent cells (ThermoFisher) or Stellar competent cells (Takara).

For the generation of truncated *alx1* constructs, the genes were divided into N-terminal and C-terminal sections, with aa181 being designated as the beginning of the C-terminal portion in zebrafish *alx1*.

For all plasmid constructs, individual clones were picked, DNA purified (Qiagen), and validated using Sanger and Next Generation whole plasmid sequencing.

CRISPR-Cas9 directed mutagenesis of zebrafish

A CRISPR site on exon 2 of the *alx1* gene was selected using the Burgess lab protocol (Varshney, Sood et al., 2015, Varshney, Zhang et al., 2016) at GGAGAGCAGCCTGCACGCGA. The single guide RNA (sgRNA) targeting this site, and Cas9 or nCas9n mRNA, were prepared as previously described (Gagnon, Valen et al., 2014, Shah, Davey et al., 2016, Shah, Moens et al., 2016). Genetically defined wildtype (NIHGRI-1) (LaFave, Varshney et al., 2014) embryos were injected at the one-cell stage with 50-

100pg of sgRNA and 360-400pg of Cas9 or nCas9n mRNA. Adult F0's animals were intercrossed to produce the F1 generation. F1 mutant carriers were identified by PCR using forward primer CGTGA~~CT~~TACTGCGCTCCTA and reverse primer CGAGTTCGTCGAGGTCTGTT. The PCR products were resolved on a MetaPhor gel (Lonza, Basel, Switzerland) and sequenced. A frame-shift allele was identified: a deletion of 16 nucleotides, termed *alx1^{uw2016}* (Supplemental Figure 4).

Alx1DN expression in zebrafish embryos

The validated Alx1DN (N-terminal portion of protein product containing homeodomain and nuclear localization domains) clones in pCS2+8 were purified via miniprep (Qiagen) alongside a control (C-terminal portion containing transactivation domain), and digested using NotI (NEB), before being gel purified using the Zymoclean Gel DNA recovery kit (Zymo Research, Irvine, CA). 500 µg of purified, digested plasmid DNA served as the input for the mMessage mMachine SP6 Transcription Kit (ThermoFisher). The resulting mRNA was then further purified using the Rneasy Mini Kit (Qiagen), and frozen in 100 ng/µL aliquots at -80°C. mRNA overexpression was accomplished using microinjections. mRNA stock aliquots were first diluted to the desired concentration with 0.125% Phenol Red in ultrapure water (Invitrogen). A 2 nL drop was then injected into fertilized Tübingen embryos at the single cell stage. At 4 hours post-fertilization (hpf), all unfertilized and visibly damaged embryos were removed.

Alcian blue staining

All injected and uninjected zebrafish were incubated at 28.5°C for 5 dpf in E3 buffer with 0.0001% methylene blue. At 4 days post-fertilization (dpf), injected and uninjected embryos were fixed overnight at 4°C in 4% formaldehyde, washed stepwise with 1XPBS and 50% EtOH in PBS before being stained in a solution of 0.02% Alcian blue, 70% EtOH, and 190mM MgCl₂ overnight at room temperature on a rotating platform. Following this, embryos were washed with ddH₂O before being bleached in a solution of 0.9% H₂O₂, 0.8% KOH, and 0.1% Tween20 for 20 minutes. Stained embryos were then imaged in 4% methylcellulose in E3 solution and stored in 4% PFA at 4°C. Images were captured using a Nikon DS-Fi3 digital camera.

Lineage tracing

The application of *Tg:sox10:kaede* in cell labeling has previously been reported, where photoconversion of the kaede protein from green to red in selected cells under confocal microscopy can be used to follow distinct NCC migration patterns across time.

Alx1DN injected or control *sox10:KAEDE* transgenic embryos were imaged using a Leica SP8 confocal microscope at 19 to 20-somite stage to identify neural crest structures in a manner previously described (Dougherty et al., 2013, Dougherty et al., 2012). The most distal population of the migrating stream of cranial neural crest cells were excited for 15 seconds for photoconversion with the FRAP module and a 405 nm laser at 25% power. Embryos were then placed back into a 28.5 °C incubator. Both the photoconverted red (488 nm) and non-photoconverted green (572 nm) neural crest populations were captured at 4 days post-fertilation (dpf) using a Leica Sp8 and analyzed with the Leica Application Suite X (Leica Microsystems, Buffalo Grove, IL) software for image capturing. A composite image was subsequently generated using ImageJ (NIH) (Figure 8D, Film 3).

Statistical analysis

Each experiment was performed on 6 independent healthy control *ALX1*^{165L/165L} clones, 3 heterozygous *ALX1*^{165L/165F} clones, and 9 homozygous *ALX1*^{165F/165F} clones, and repeated at least three times. The qualitative craniofacial analysis of *alx1*^{-/-} zebrafish and Alx1DN injections was performed three times, on three different clutches of embryos. For RT-qPCR experiment, data from each clone were pooled and the mathematical mean was calculated. SEM was used to determine the standard error. To test statistical significance, the Student's t-test for paired data was used. Statistical analysis of the significance of the qPCR results was performed with an ANOVA test. A p-value <0.05 was considered to be statistically significant. Statistical analysis was performed using GraphPad Prism 7.0 software. The D'Agostino & Pearson normality test was performed to verify normality. For groups that fulfilled normality and equal variance requirements, a one-way ANOVA with a Sidak's comparison test (95% confidence interval to compare all the different groups) was performed. For data sets that did not fulfill normality and equal variance requirements, a Kruskal-Wallis test was performed. Mean values for each group were compared using the two-tailed Student's test for comparisons of two independent groups.

ACKNOWLEDGMENTS

We are grateful for Shriners Hospital for Children and National Institute of Health U01DE024443 for funding that supported this work. ECL is a recipient of the Massachusetts General Laurie and Mason Tenaglia Research Scholar award. JK is a recipient of the Shriners Hospital Research Fellowship. We thank Jessica Bathoney for excellent management of our aquatics facility.

AUTHOR CONTRIBUTION

JP, JK and ECL conceived of the project and designed the research studies. JP, JK, YDH, CT, KK, PY, BY and AKTP conducted the experiments; JP, JK, CT, NC, VP, RLM, YG and ECL prepared the manuscript. JK, CT and ECL worked on the revision of the manuscript.

CONFLICTS OF INTEREST

The authors state that they have no conflict of interest with regard to any of the work herein presented.

THE PAPER EXPLAINED

Problem. The causes of malformations of the human face remain poorly understood. This lack of understanding results in limited treatment and counseling options, specifically in families affected by malformations linked to a genetic cause. One such gene is called *ALX1*. This study aimed to understand the role of this gene in the development of the face, and the effect of mutations of the gene in the genesis of malformation. To do so, we reprogrammed blood cells from children affected by *ALX1*-related malformations of the face into stem cells which allow us to retrace development. Additionally, we created a disruption of the gene in zebrafish in order to model the malformation in an animal and understand the role of the gene in development more broadly.

Results. *ALX1* was found to be crucial to the development of a cell population which exists only during a limited time of early development, termed Neural Crest Cells. These cells form while the early structures which will come to form the nervous system grow. They migrate to the front of the embryo to form the face. The cells of patients bearing a mutation of *ALX1* were found to be more likely to die when compared with cells derived from healthy donors. They were also found to show a migration defect. Similar differences were observed in the zebrafish models of the disease created by a disruption of the same gene.

Impact. Understanding the causes of malformations of the face will give us the tools to innovate and transform the insufficient treatment options currently available to patients.

REFERENCES

- Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR (2010) A method and server for predicting damaging missense mutations. *Nat Methods* 7: 248-9
- Anderson RM, Stottmann RW, Choi M, Klingensmith J (2006) Endogenous bone morphogenetic protein antagonists regulate mammalian neural crest generation and survival. *Dev Dyn* 235: 2507-20
- Bajpai R, Chen DA, Rada-Iglesias A, Zhang J, Xiong Y, Helms J, Chang CP, Zhao Y, Swigut T, Wysocka J (2010) CHD7 cooperates with PBAF to control multipotent neural crest formation. *Nature* 463: 958-62
- Barrallo-Gimeno A, Holzschuh J, Driever W, Knapik EW Neural crest survival and differentiation in zebrafish depends on mont blanc/tfap2a gene function. *Development* 131: 1463-1477
- Barrallo-Gimeno A, Holzschuh J, Driever W, Knapik EW (2004) Neural crest survival and differentiation in zebrafish depends on mont blanc/tfap2a gene function. *Development* 131: 1463-77
- Betancur P, Bronner-Fraser M, Sauka-Spengler T (2010) Assembling neural crest regulatory circuits into a gene regulatory network. *Annu Rev Cell Dev Biol* 26: 581-603
- Beverdam A, Brouwer A, Reijnen M, Korving J, Meijlink F (2001) Severe nasal clefting and abnormal embryonic apoptosis in *Alx3/Alx4* double mutant mice. *Development* 128: 3975-86
- Beverdam A, Meijlink F (2001) Expression patterns of group-I aristaless-related genes during craniofacial and limb development. *Mech Dev* 107: 163-7
- Bhoj EJ, Li D, Harr MH, Tian L, Wang T, Zhao Y, Qiu H, Kim C, Hoffman JD, Hakonarson H, Zackai EH (2015) Expanding the SPECC1L mutation phenotypic spectrum to include Teebi hypertelorism syndrome. *Am J Med Genet A* 167A: 2497-502
- Billon N, Iannarelli P, Monteiro MC, Glavieux-Pardanaud C, Richardson WD, Kessar N, Dani C, Dupin E (2007) The generation of adipocytes by the neural crest. *Development* 134: 2283-92
- Cai RL (1998) Human CART1, a Paired-Class Homeodomain Protein, Activates Transcription through Palindromic Binding Sites. *Biochemical and Biophysical Research Communications* 250: 305-311
- Chai Y, Jiang X, Ito Y, Bringas P, Jr., Han J, Rowitch DH, Soriano P, McMahon AP, Sucov HM Fate of the mammalian cranial neural crest during tooth and mandibular morphogenesis. *Development* 127: 1671-1679
- Damle S, Davidson EH (2011) Precise cis-regulatory control of spatial and temporal expression of the *alx-1* gene in the skeletogenic lineage of *S. purpuratus*. *Developmental Biology* 357: 505-517
- Dee CT, Szymoniuk CR, Mills PE, Takahashi T (2013a) Defective neural crest migration revealed by a Zebrafish model of *Alx1*-related frontonasal dysplasia. *Hum Mol Genet* 22: 239-251
- Dee CT, Szymoniuk CR, Mills PED, Takahashi T (2013b) Defective neural crest migration revealed by a Zebrafish model of *Alx1*-related frontonasal dysplasia. *Human Molecular Genetics* 22: 239-251
- Dougherty M, Kamel G, Grimaldi M, Gfrerer L, Shubinets V, Ethier R, Hickey G, Cornell RA, Liao EC (2013) Distinct requirements for *wnt9a* and *irf6* in extension and integration mechanisms during zebrafish palate morphogenesis. *Development* 140: 76-81
- Dougherty M, Kamel G, Shubinets V, Hickey G, Grimaldi M, Liao EC Embryonic fate map of first pharyngeal arch structures in the *sox10: kaede* zebrafish transgenic model. *J Craniofac Surg* 23: 1333-1337
- Dougherty M, Kamel G, Shubinets V, Hickey G, Grimaldi M, Liao EC (2012) Embryonic fate map of first pharyngeal arch structures in the *sox10: kaede* zebrafish transgenic model. *J Craniofac Surg* 23: 1333-7
- Eberhart JK (2006) Early Hedgehog signaling from neural to oral epithelium organizes anterior craniofacial development. *Development* 133: 1069-1077
- El-Brolosy MA, Kontarakis Z, Rossi A, Kuenne C, Gunther S, Fukuda N, Kikhi K, Boezio GLM, Takacs CM, Lai SL, Fukuda R, Gerri C, Giraldez AJ, Stainier DYR (2019) Genetic compensation triggered by mutant mRNA degradation. *Nature* 568: 193-197
- Ettensohn CA, Illies MR, Oliveri P, De Jong DL (2003) *Alx1*, a member of the *Cart1/Alx3/Alx4* subfamily of Paired-class homeodomain proteins, is an essential component of the gene network controlling skeletogenic fate specification in the sea urchin embryo. *Development* 130: 2917-28
- Fox JW, Golden GT, Edgerton MT Frontonasal dysplasia with alar clefts in two sisters. Genetic considerations and surgical correction. *Plast Reconstr Surg* 57: 553-561
- Furukawa K, Iioka T, Morishita M, Yamaguchi A, Shindo H, Namba H, Yamashita S, Tsukazaki T (2002) Functional domains of paired-like homeoprotein *Cart1* and the relationship between dimerization and transcription activity. *Genes to Cells: Devoted to Molecular & Cellular Mechanisms* 7: 1135-1147
- Gagnon JA, Valen E, Thyme SB, Huang P, Akhmetova L, Pauli A, Montague TG, Zimmerman S, Richter C, Schier AF (2014) Efficient mutagenesis by Cas9 protein-mediated oligonucleotide insertion and large-scale assessment of single-guide RNAs. *PLoS One* 9: e98186
- Garnett AT, Square TA, Medeiros DM (2012) BMP, Wnt and FGF signals are integrated through evolutionarily conserved enhancers to achieve robust expression of *Pax3* and *Zic* genes at the zebrafish neural plate border. *Development* 139: 4220-31

- Gomez CM, Gammack JT (1995) A leucine-to-phenylalanine substitution in the acetylcholine receptor ion channel in a family with the slow-channel syndrome. *Neurology* 45: 982-5
- Gordon DF, Wagner J, Atkinson BL, Chiono M, Berry R, Sikela J, Gutierrez-Hartmann A (1996) Human Cart-1: Structural Organization, Chromosomal Localization, and Functional Analysis of a Cartilage-Specific Homeodomain cDNA. *DNA and Cell Biology* 15: 531-541
- Hayashi M, Nimura K, Kashiwagi K, Harada T, Takaoka K, Kato H, Tamai K, Kaneda Y (2007) Comparative roles of Twist-1 and Id1 in transcriptional regulation by BMP signaling. *J Cell Sci* 120: 1350-7
- Herskowitz I (1987) Functional inactivation of genes by dominant negative mutations. *Nature* 329: 219-222
- Huang S, Wang Y, Luo L, Li X, Jin X, Li S, Yu X, Yang M, Guo Z (2019a) BMP2 Is Related to Hirschsprung's Disease and Required for Enteric Nervous System Development. *Front Cell Neurosci* 13: 523
- Huang X, Wang F, Zhao C, Yang S, Cheng Q, Tang Y, Zhang F, Zhang Y, Luo W, Wang C, Zhou P, Kim S, Zuo G, Hu N, Li R, He TC, Zhang H (2019b) Dentinogenesis and Tooth-Alveolar Bone Complex Defects in BMP9/GDF2 Knockout Mice. *Stem Cells Dev* 28: 683-694
- Johnston MC The neural crest in abnormalities of the face and brain. *Birth Defects Orig Artic Ser* 11: 1-18
- Johnston MC (1966) A radioautographic study of the migration and fate of cranial neural crest cells in the chick embryo. *The Anatomical Record* 156: 143-155
- Kanzler B, Foreman RK, Labosky PA, Mallo M (2000) BMP signaling is essential for development of skeletogenic and neurogenic cranial neural crest. *Development* 127: 1095-104
- Karczewski K.J, LCF, Grace Tiao, Beryl B. Cummings, Jessica Alföldi, Qingbo Wang, Ryan L. Collins, Kristen M. Laricchia, Andrea Ganna, Daniel P. Birnbaum, Laura D. Gauthier, Harrison Brand, Matthew Solomonson, Nicholas A. Watts, Daniel Rhodes, Moriel Singer-Berk, Eleina M. England, Eleanor G. Seaby, Jack A. Kosmicki, Raymond K. Walters, Katherine Tashman, Yossi Farjoun, Eric Banks, Timothy Poterba, Arcturus Wang, Cotton Seed, Nicola Whiffin, Jessica X. Chong, Kaitlin E. Samocha, Emma Pierce-Hoffman, Zachary Zappala, Anne H. O'Donnell-Luria, Eric Vallabh Minikel, Ben Weisburd, Monkol Lek, James S. Ware, Christopher Vittal, Irina M. Armean, Louis Bergelson, Kristian Cibulskis, Kristen M. Connolly, Miguel Covarrubias, Stacey Donnelly, Steven Ferriera, Stacey Gabriel, Jeff Gentry, Namrata Gupta, Thibault Jeandet, Diane Kaplan, Christopher Llanwarne, Ruchi Munshi, Sam Novod, Nikelle Petrillo, David Roazen, Valentin Ruano-Rubio, Andrea Saltzman, Molly Schleicher, Jose Soto, Kathleen Tibbetts, Charlotte Tolonen, Gordon Wade, Michael E. Talkowski, Genome Aggregation Database (gnomAD) Consortium, Benjamin M. Neale, Mark J. Daly, Daniel G. MacArthur (2019) The mutational constraint spectrum quantified from variation in 141,456 humans. In bioRxiv:
- Kawano E, Toriumi T, Iguchi S, Suzuki D, Sato S, Honda M (2017) Induction of neural crest cells from human dental pulp-derived induced pluripotent stem cells. *Biomed Res* 38: 135-147
- Kayserili H, Uz E, Niessen C, Vargel I, Alanay Y, Tuncbilek G, Yigit G, Uyguner O, Candan S, Okur H, Kaygin S, Balci S, Mavili E, Alikasifoglu M, Haase I, Wollnik B, Akarsu NA (2009) ALX4 dysfunction disrupts craniofacial and epidermal development. *Hum Mol Genet* 18: 4357-66
- Khudyakov J, Bronner-Fraser M (2009) Comprehensive spatiotemporal analysis of early chick neural crest network genes. *Dev Dyn* 238: 716-23
- LaFave MC, Varshney GK, Vemulapalli M, Mullikin JC, Burgess SM (2014) A defined zebrafish line for high-throughput genetics and genomics: NHGRI-1. *Genetics* 198: 167-70
- Lamplot JD, Qin J, Nan G, Wang J, Liu X, Yin L, Tomal J, Li R, Shui W, Zhang H, Kim SH, Zhang W, Zhang J, Kong Y, Denduluri S, Rogers MR, Pratt A, Haydon RC, Luu HH, Angeles J et al. (2013) BMP9 signaling in stem cell differentiation and osteogenesis. *Am J Stem Cells* 2: 1-21
- Le Douarin NM, Ziller C, Couly GF (1993) Patterning of neural crest derivatives in the avian embryo: in vivo and in vitro studies. *Developmental Biology* 159: 24-49
- Le Lièvre CS (1978) Participation of neural crest-derived cells in the genesis of the skull in birds. *Journal of Embryology and Experimental Morphology* 47: 17-37
- Le Lièvre CS, Le Douarin NM (1975) Mesenchymal derivatives of the neural crest: analysis of chimaeric quail and chick embryos. *Journal of Embryology and Experimental Morphology* 34: 125-154
- Leung AW, Murdoch B, Salem AF, Prasad MS, Gomez GA, Garcia-Castro MI (2016) WNT/beta-catenin signaling mediates human neural crest induction via a pre-neural border intermediate. *Development* 143: 398-410
- Lours-Calet C, Alvares LE, El-Hanfy AS, Gandesha S, Walters EH, Sobreira DR, Wotton KR, Jorge EC, Lawson JA, Kelsey Lewis A, Tada M, Sharpe C, Kardon G, Dietrich S (2014) Evolutionarily conserved morphogenetic movements at the vertebrate head-trunk interface coordinate the transport and assembly of hypopharyngeal structures. *Dev Biol* 390: 231-46
- Lowe D (1999) Object Recognition from Local Scale-Invariant Features. *Proceedings of the International Conference on Computer Vision* 2

- Luther G, Wagner ER, Zhu G, Kang Q, Luo Q, Lamplot J, Bi Y, Luo X, Luo J, Teven C, Shi Q, Kim SH, Gao JL, Huang E, Yang K, Rames R, Liu X, Li M, Hu N, Liu H et al. (2011) BMP-9 induced osteogenic differentiation of mesenchymal stem cells: molecular mechanism and therapeutic potential. *Curr Gene Ther* 11: 229-40
- Mavrogiannis LA, Antonopoulou I, Baxova A, Kutilek S, Kim CA, Sugayama SM, Salamanca A, Wall SA, Morriss-Kay GM, Wilkie AO (2001) Haploinsufficiency of the human homeobox gene ALX4 causes skull ossification defects. *Nat Genet* 27: 17-8
- McGonnell IM, Graham A, Richardson J, Fish JL, Depew MJ, Dee CT, Holland PWH, Takahashi T (2011) Evolution of the Alx homeobox gene family: parallel retention and independent loss of the vertebrate Alx3 gene: Evolution of vertebrate Alx homeobox genes. *Evolution & Development* 13: 343-351
- McGurk PD, Lovely CB, Eberhart JK (2014) Analyzing craniofacial morphogenesis in zebrafish using 4D confocal microscopy. *J Vis Exp*: e51190
- Meulemans D, Bronner-Fraser M (2002) Amphioxus and lamprey AP-2 genes: implications for neural crest evolution and migration patterns. *Development* 129: 4953-62
- Miller JL, Lyle VA, Cunningham D (1992) Mutation of leucine-57 to phenylalanine in a platelet glycoprotein Ib alpha leucine tandem repeat occurring in patients with an autosomal dominant variant of Bernard-Soulier disease. *Blood* 79: 439-46
- Minarick JC, Golden JA (2003) AP-2 and HNK-1 define distinct populations of cranial neural crest cells. *Orthod Craniofac Res* 6: 210-9
- Minarikova P, Benesova L, Halkova T, Belsanova B, Tuckova I, Belina F, Dusek L, Zavoral M, Minarik M (2016) Prognostic Importance of Cell Cycle Regulators Cyclin D1 (CCND1) and Cyclin-Dependent Kinase Inhibitor 1B (CDKN1B/p27) in Sporadic Gastric Cancers. *Gastroenterol Res Pract* 2016: 9408190
- Minoux M, Rijli FM Molecular mechanisms of cranial neural crest cell migration and patterning in craniofacial development. *Development* 137: 2605-2621
- Okuno H, Renault Mihara F, Ohta S, Fukuda K, Kurosawa K, Akamatsu W, Sanosaka T, Kohyama J, Hayashi K, Nakajima K, Takahashi T, Wysocka J, Kosaki K, Okano H CHARGE syndrome modeling using patient-iPSCs reveals defective migration of neural crest cells harboring CHD7 mutations. *Elife* 6
- Olsson L, Moury DJ, Carl TF, Hastad O, Hanken J Cranial neural crest-cell migration in the direct-developing frog, *Eleutherodactylus coqui*: molecular heterogeneity within and among migratory streams. *Zoology (Jena)* 105: 3-13
- Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G (1992) Cyclin A is required at two points in the human cell cycle. *EMBO J* 11: 961-71
- Pierpont ME, Basson CT, Benson DW, Jr., Gelb BD, Giglia TM, Goldmuntz E, McGee G, Sable CA, Srivastava D, Webb CL, American Heart Association Congenital Cardiac Defects Committee CoCDitY (2007) Genetic basis for congenital heart defects: current knowledge: a scientific statement from the American Heart Association Congenital Cardiac Defects Committee, Council on Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics. *Circulation* 115: 3015-38
- Pini J, Giuliano S, Matonti J, Gannoun L, Simkin D, Rouleau M, Bendahhou S (2018) Osteogenic and Chondrogenic Master Genes Expression Is Dependent on the Kir2.1 Potassium Channel Through the Bone Morphogenetic Protein Pathway. *J Bone Miner Res* 33: 1826-1841
- Qu S, Li L, Wisdom R (1997) Alx-4: cDNA cloning and characterization of a novel paired-type homeodomain protein. *Gene* 203: 217-23
- Rada-Iglesias A, Prescott SL, Wysocka J Human genetic variation within neural crest enhancers: molecular and phenotypic implications. *Philos Trans R Soc Lond B Biol Sci* 368: 20120360
- Ren J, Wen L, Gao X, Jin C, Xue Y, Yao X (2009) DOG 1.0: illustrator of protein domain structures. *Cell Res* 19: 271-3
- Sadaghiani B, Thiébaud CH (1987) Neural crest development in the *Xenopus laevis* embryo, studied by interspecific transplantation and scanning electron microscopy. *Developmental Biology* 124: 91-110
- Sato T, Sasai N, Sasai Y (2005) Neural crest determination by co-activation of Pax3 and Zic1 genes in *Xenopus* ectoderm. *Development* 132: 2355-63
- Sauka-Spengler T, Bronner-Fraser M (2008) A gene regulatory network orchestrates neural crest formation. *Nat Rev Mol Cell Biol* 9: 557-68
- Sauka-Spengler T, Meulemans D, Jones M, Bronner-Fraser M (2007) Ancient evolutionary origin of the neural crest gene regulatory network. *Dev Cell* 13: 405-20
- Schilling TF, Walker C, Kimmel CB The chinless mutation and neural crest cell interactions in zebrafish jaw development. *Development* 122: 1417-1426
- Schwarz JM, Cooper DN, Schuelke M, Seelow D (2014) MutationTaster2: mutation prediction for the deep-sequencing age. *Nat Methods* 11: 361-2
- Sedano HO, Cohen MM, Jr., Jirasek J, Gorlin RJ Frontonasal dysplasia. *J Pediatr* 76: 906-913

- Shah AN, Davey CF, Whitebirch AC, Miller AC, Moens CB (2016) Rapid Reverse Genetic Screening Using CRISPR in Zebrafish. *Zebrafish* 13: 152-3
- Shah AN, Moens CB, Miller AC (2016) Targeted candidate gene screens using CRISPR/Cas9 technology. *Methods Cell Biol* 135: 89-106
- Shihab HA, Gough J, Mort M, Cooper DN, Day IN, Gaunt TR (2014) Ranking non-synonymous single nucleotide polymorphisms based on disease concepts. *Hum Genomics* 8: 11
- Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, Lopez R, McWilliam H, Remmert M, Soding J, Thompson JD, Higgins DG (2011) Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. *Mol Syst Biol* 7: 539
- Simoes-Costa M, Bronner ME (2015) Establishing neural crest identity: a gene regulatory recipe. *Development* 142: 242-57
- Smith JD, Hing AV, Clarke CM, Johnson NM, Perez FA, Park SS, Horst JA, Mecham B, Maves L, Nickerson DA, University of Washington Center for Mendelian G, Cunningham ML (2014) Exome sequencing identifies a recurrent de novo ZSWIM6 mutation associated with acromelic frontonasal dysostosis. *Am J Hum Genet* 95: 235-40
- Stuhlmiller TJ, Garcia-Castro MI (2012) Current perspectives of the signaling pathways directing neural crest induction. *Cell Mol Life Sci* 69: 3715-37
- Tchieu J, Zimmer B, Fattahi F, Amin S, Zeltner N, Chen S, Studer L (2017) A Modular Platform for Differentiation of Human PSCs into All Major Ectodermal Lineages. *Cell Stem Cell* 21: 399-410 e7
- ten Berge D, Brouwer A, el Bahi S, Guenet JL, Robert B, Meijlink F (1998) Mouse *Alx3*: an aristaless-like homeobox gene expressed during embryogenesis in ectomesenchyme and lateral plate mesoderm. *Dev Biol* 199: 11-25
- Trainor PA, Sobieszczuk D, Wilkinson D, Krumlauf R Signalling between the hindbrain and paraxial tissues dictates neural crest migration pathways. *Development* 129: 433-442
- Tribulo C, Aybar MJ, Nguyen VH, Mullins MC, Mayor R (2003) Regulation of *Msx* genes by a *Bmp* gradient is essential for neural crest specification. *Development* 130: 6441-52
- Twigg SR, Kan R, Babbs C, Bochukova EG, Robertson SP, Wall SA, Morriss-Kay GM, Wilkie AO (2004) Mutations of ephrin-B1 (*EFNB1*), a marker of tissue boundary formation, cause craniofrontonasal syndrome. *Proc Natl Acad Sci U S A* 101: 8652-7
- Twigg SR, Versnel SL, Nurnberg G, Lees MM, Bhat M, Hammond P, Hennekam RC, Hoogeboom AJ, Hurst JA, Johnson D, Robinson AA, Scambler PJ, Gerrelli D, Nurnberg P, Mathijssen IM, Wilkie AO (2009) Frontorhiny, a distinctive presentation of frontonasal dysplasia caused by recessive mutations in the *ALX3* homeobox gene. *Am J Hum Genet* 84: 698-705
- Ullah A, Kalsoom UE, Umair M, John P, Ansar M, Basit S, Ahmad W (2016) Exome sequencing revealed a novel splice site variant in the *ALX1* gene underlying frontonasal dysplasia. *Clin Genet*
- Umm-e-Kalsoom, Basit S, Kamran-ul-Hassan Naqvi S, Ansar M, Ahmad W (2012) Genetic mapping of an autosomal recessive postaxial polydactyly type A to chromosome 13q13.3–q21.2 and screening of the candidate genes. *Human Genetics* 131: 415-422
- Uz E, Alanay Y, Aktas D, Vargel I, Gucer S, Tuncbilek G, von Eggeling F, Yilmaz E, Deren O, Posorski N, Ozdag H, Liehr T, Balci S, Alikasifoglu M, Wollnik B, Akarsu NA (2010) Disruption of *ALX1* Causes Extreme Microphthalmia and Severe Facial Clefting: Expanding the Spectrum of Autosomal-Recessive *ALX*-Related Frontonasal Dysplasia. *The American Journal of Human Genetics* 86: 789-796
- Varshney GK, Sood R, Burgess SM (2015) Understanding and Editing the Zebrafish Genome. *Adv Genet* 92: 1-52
- Varshney GK, Zhang S, Pei W, Adomako-Ankomah A, Fohitung J, Schaffer K, Carrington B, Maskeri A, Slevin C, Wolfsberg T, Ledin J, Sood R, Burgess SM (2016) CRISPRz: a database of zebrafish validated sgRNAs. *Nucleic Acids Res* 44: D822-6
- Wada N (2005) Hedgehog signaling is required for cranial neural crest morphogenesis and chondrogenesis at the midline in the zebrafish skull. *Development* 132: 3977-3988
- Wada N, Javidan Y, Nelson S, Carney TJ, Kelsh RN, Schilling TF (2005) Hedgehog signaling is required for cranial neural crest morphogenesis and chondrogenesis at the midline in the zebrafish skull. *Development* 132: 3977-88
- Wang Y, Hong S, Li M, Zhang J, Bi Y, He Y, Liu X, Nan G, Su Y, Zhu G, Li R, Zhang W, Wang J, Zhang H, Kong Y, Shui W, Wu N, He Y, Chen X, Luu HH et al. (2013) Noggin resistance contributes to the potent osteogenic capability of BMP9 in mesenchymal stem cells. *J Orthop Res* 31: 1796-803
- Wieland I, Jakubiczka S, Muschke P, Cohen M, Thiele H, Gerlach KL, Adams RH, Wieacker P (2004) Mutations of the ephrin-B1 gene cause craniofrontonasal syndrome. *Am J Hum Genet* 74: 1209-15

Wu YQ, Badano JL, McCaskill C, Vogel H, Potocki L, Shaffer LG (2000) Haploinsufficiency of ALX4 as a potential cause of parietal foramina in the 11p11.2 contiguous gene-deletion syndrome. *Am J Hum Genet* 67: 1327-32

Wuyts W, Cleiren E, Homfray T, Rasore-Quartino A, Vanhoenacker F, Van Hul W (2000) The ALX4 homeobox gene is mutated in patients with ossification defects of the skull (foramina parietalia permagna, OMIM 168500). *J Med Genet* 37: 916-20

Zhao GQ, Eberspaecher H, Seldin MF, de Crombrughe B (1994) The gene for the homeodomain-containing protein Cart-1 is expressed in cells that have a chondrogenic potential during embryonic development. *Mech Dev* 48: 245-54

Zhao Q, Behringer RR, de Crombrughe B (1996a) Prenatal folic acid treatment suppresses acrania and meroanencephaly in mice mutant for the Cart1 homeobox gene. *Nat Genet* 13: 275-283

Zhao Q, Behringer RR, de Crombrughe B (1996b) Prenatal folic acid treatment suppresses acrania and meroanencephaly in mice mutant for the Cart1 homeobox gene. *Nat Genet* 13: 275-83

Table 1: Comparative FACS analysis of subject-derived $ALX1^{165F/165F}$ and control NCC at passages 1 and 4.

	Passage 1		Passage 4	
	Control ($ALX1^{165L/165L}$)	$ALX1^{165F/165F}$	Control ($ALX1^{165L/165L}$)	$ALX1^{165F/165F}$
CD57	45.6 ± 7.7%	57.4 ± 7.3%	6.78 ± 2.36 %	49.55 ± 17.53%
CD90	55.05 ± 5.24%	63.6 ± 6.9%	88.46 ± 2.05 %	67.8 ± 11.07%
CD105	51.7 ± 7.8%	47.6 ± 11.4%	96.31 ± 0.95 %	60.02 ± 12.66%
CD73	97.4 ± 1.08%	79.2 ± 9.6%	98.8 ± 0.44 %	83.95 ± 6.05%

Supplemental Table 1: P-values for Figure 3.

*: Significant differences when compared to undifferentiated iPSC.

ALX1							
Day	2	4	6	8	10	12	14
	ALX1^{165F/165F}						
Undifferentiated	p=0.0024	p=5e ⁻¹¹	p=8e ⁻¹³	p=4e ⁻¹¹	p=4e ⁻⁸	p=7e ⁻¹³	p=6e ⁻¹⁴
	ALX1^{165L/165F}						
Undifferentiated	NS	p=0.000001	p=5e ⁻¹⁰	p=1e ⁻⁷	p=1e ⁻⁸	p=6e ⁻⁹	p=2e ⁻⁷
	Control (ALX1^{165L/165L})						
Undifferentiated	NS	NS	p=4e ⁻⁸	p=7e ⁻¹³	p=0.0002	p=0.00002	p=1e ⁻⁶

ZIC1							
Day	2	4	6	8	10	12	14
	ALX1^{165F/165F}						
Undifferentiated	p=0.0005	p=0.0245	p=0.0158	p=0.0029	NS	NS	NS
	ALX1^{165L/165F}						
Undifferentiated	p=0.0261	NS	NS	NS	NS	NS	NS
	Control (ALX1^{165L/165L})						
Undifferentiated	p=0.0016	NS	NS	NS	NS	NS	NS

PAX7							
Day	2	4	6	8	10	12	14
	ALX1^{165F/165F}						
Undifferentiated	p=0.0163	p=0.0076	p=0.0092	p=0.0136	NS	NS	NS
	ALX1^{165L/165F}						
Undifferentiated	NS	p=0.0257	NS	NS	NS	NS	NS
	Control (ALX1^{165L/165L})						
Undifferentiated	NS	p=0.0425	NS	NS	NS	NS	NS

PAX3							
Day	2	4	6	8	10	12	14
	ALX1^{165F/165F}						
Undifferentiated	p=0.00008	p=1e ⁻⁷	p=4e ⁻⁹	p=1e ⁻⁶	p=0.0329	p=0.0008	p=0.0108
	ALX1^{165L/165F}						
Undifferentiated	NS	p=0.0024	p=0.0036	p=0.0007	p=0.0456	p=0.0247	p=0.0387

	Control (ALX1 ^{165L/165L})						
Undifferentiated	NS	p=5e ⁻⁶	p=6e ⁻¹⁰	p=3e ⁻¹⁰	p=0.0068	p=0.0034	NS

MSX1							
Day	2	4	6	8	10	12	14
	ALX1 ^{165F/165F}						
Undifferentiated	p=2e ⁻⁷	p=3e ⁻¹⁵	p=1e ⁻¹²	p=2e ⁻¹⁴	p=1e ⁻¹⁵	p=5e ⁻¹¹	p=13e ⁻¹⁴
	ALX1 ^{165L/165F}						
Undifferentiated	NS	p=1e ⁻⁷	p=0.0004	p=1e ⁻⁷	p=3e ⁻⁹	p=1e ⁻¹⁰	p=7e ⁻⁹
	Control (ALX1 ^{165L/165L})						
Undifferentiated	NS	p=1e ⁻⁶	p=8e ⁻¹²	p=6e ⁻¹¹	p=3e ⁻⁹	p=2e ⁻⁹	p=1e ⁻⁹

MSX2							
Day	2	4	6	8	10	12	14
	ALX1 ^{165F/165F}						
Undifferentiated	p=1e ⁻¹⁵	p=7e ⁻¹³	p=1e ⁻¹⁰	p=8e ⁻¹⁵	p=6e ⁻¹²	p=1e ⁻¹⁵	p=1e ⁻¹⁴
	ALX1 ^{165L/165F}						
Undifferentiated	p=9e ⁻¹²	p=1e ⁻¹⁵	p=6e ⁻⁸	p=8e ⁻¹³	p=1e ⁻¹⁵	p=3e ⁻¹²	p=1e ⁻¹⁵
	Control (ALX1 ^{165L/165L})						
Undifferentiated	NS	p=3e ⁻⁶	p=7e ⁻⁶	p=2e ⁻⁸	p=0.0007	p=0.0002	p=0.0011

DLX5							
Day	2	4	6	8	10	12	14
	ALX1 ^{165F/165F}						
Undifferentiated	p=1e ⁻⁸	p=3e ⁻¹⁵	p=2e ⁻¹⁰	p=1e ⁻¹⁵	p=1e ⁻¹⁴	p=6e ⁻¹¹	p=8e ⁻¹²
	ALX1 ^{165L/165F}						
Undifferentiated	p=7e ⁻⁷	p=1e ⁻¹¹	p=1e ⁻⁸	p=3e ⁻⁹	p=1e ⁻⁹	p=6e ⁻¹²	p=7e ⁻⁸
	Control (ALX1 ^{165L/165L})						
Undifferentiated	NS	p=0.0008	p=0.0048	p=0.0186	NS	NS	NS

FOX3							
Day	2	4	6	8	10	12	14
	ALX1 ^{165F/165F}						
Undifferentiated	p=0.0182	NS	NS	NS	NS	NS	NS
	ALX1 ^{165L/165F}						

Undifferentiated	$p=1e^{-6}$	NS	NS	NS	NS	NS	NS
Control (ALX1^{165L/165L})							
Undifferentiated	$p=0.0013$	NS	NS	NS	NS	NS	NS

P75							
Day	2	4	6	8	10	12	14
ALX1^{165F/165F}							
Undifferentiated	$p=0.0002$	NS	NS	NS	NS	NS	NS
ALX1^{165L/165F}							
Undifferentiated	$p=0.0210$	NS	NS	NS	NS	NS	NS
Control (ALX1^{165L/165L})							
Undifferentiated	$p=0.0082$	NS	NS	NS	NS	NS	NS

TFAP2A							
Day	2	4	6	8	10	12	14
ALX1^{165F/165F}							
Undifferentiated	$p=2e^{-8}$	$p=3e^{-12}$	$p=5e^{-12}$	$p=1e^{-13}$	$p=3e^{-10}$	$p=5e^{-10}$	$p=7e^{-10}$
ALX1^{165L/165F}							
Undifferentiated	$p=5e^{-9}$	$p=9e^{-12}$	$p=2e^{-10}$	$p=1e^{-15}$	$p=7e^{-14}$	$p=1e^{-15}$	$p=1e^{-14}$
Control (ALX1^{165L/165L})							
Undifferentiated	NS	$p=0.00009$	$p=0.0126$	$p=2e^{-7}$	$p=0.0001$	$p=0.0001$	NS

SNAI2							
Day	2	4	6	8	10	12	14
ALX1^{165F/165F}							
Undifferentiated	$p=0.0000009$	$p=1e^{-15}$	$p=7e^{-12}$	$p=6e^{-14}$	$p=1e^{-15}$	$p=3e^{-11}$	$p=1e^{-14}$
ALX1^{165L/165F}							
Undifferentiated	$p=0.0211$	$p=1e^{-8}$	$p=6e^{-12}$	$p=8e^{-15}$	$p=1e^{-13}$	$p=1e^{-15}$	$p=6e^{-9}$
Control (ALX1^{165L/165L})							
Undifferentiated	NS	$p=7e^{-6}$	$p=1e^{-15}$	$p=6e^{-13}$	$p=4e^{-8}$	$p=8e^{-14}$	$p=1e^{-15}$

HAND2							
Day	2	4	6	8	10	12	14
ALX1^{165F/165F}							
Undifferentiated	$p=0.0004$	$p=6e^{-7}$	$p=3e^{-12}$	$p=1e^{-15}$	$p=5e^{-14}$	$p=1e^{-12}$	$p=6e^{-11}$

	ALX1^{165L/165F}						
Undifferentiated	NS	NS	NS	p=0.0022	p=0.0003	p=0.000008	p=0.00003
	Control (ALX1^{165L/165L})						
Undifferentiated	NS	NS	p=0.0019	p=0.0001	p=0.0127	p=0.0027	p=0.0019

** : Significant differences when comparing undifferentiated iPSCs, $ALX1^{165L/165L}$ and $ALX1^{165L/165F}$ iPSC.

ALX1							
Day	2	4	6	8	10	12	14
	$ALX1^{165F/165F}$						
$ALX1^{165L/165L}$	NS	p=0.0002	NS	p=2e ⁻⁸	NS	NS	NS
$ALX1^{165L/165F}$	NS	NS	NS	p=0.0021	NS	NS	NS

ZIC1							
Day	2	4	6	8	10	12	14
	$ALX1^{165F/165F}$						
$ALX1^{165L/165L}$	p=0.003	p=0.0017	p=0.0014	p=1e ⁻⁶	NS	NS	NS
$ALX1^{165L/165F}$	p=1e ⁻¹	p=5e ⁻¹⁵	p=3e ⁻¹⁵	p=1e ⁻¹⁵	NS	NS	NS

PAX7							
Day	2	4	6	8	10	12	14
	$ALX1^{165F/165F}$						
$ALX1^{165L/165L}$	p=2e ⁻¹⁰	p=1e ⁻¹⁵	p=6e ⁻⁷	p=0.0147	NS	NS	NS
$ALX1^{165L/165F}$	p=4e ⁻¹³	p=2e ⁻⁹	p=3e ⁻¹¹	p=2e ⁻⁶	NS	NS	NS

PAX3							
Day	2	4	6	8	10	12	14
	$ALX1^{165F/165F}$						
$ALX1^{165L/165L}$	p=0.0000006	p=0.000009	p=0.0012	p=0.0152	p=0.0003	p=0.0017	p=0.00132
$ALX1^{165L/165F}$	p=0.0003	p=7e ⁻⁸	p=2e ⁻¹⁰	p=9e ⁻⁶	p=0.0045	p=0.0058	p=0.0001

MSX1							
Day	2	4	6	8	10	12	14
	$ALX1^{165F/165F}$						
$ALX1^{165L/165L}$	NS	p=0.0128	p=0.0235	p=0.0001	p=0.0016	p=0.00002	p=0.0007
$ALX1^{165L/165F}$	NS	p=0.000001	p=4e ⁻⁸	p=3e ⁻⁸	p=0.00001	p=0.00006	p=0.0003

MSX2							
Day	2	4	6	8	10	12	14
	ALX1^{165F/165F}						
ALX1^{165L/165L}	p=7e ⁻¹³	p=1e ⁻¹⁵	p=0.0134	p=5e ⁻¹⁵	p=3e ⁻¹⁵	p=6e ⁻¹⁵	p=1e ⁻¹⁵
ALX1^{165L/165F}	p=0.003	p=0.0055	p=0.008	p= p=6e ⁻⁶ 0	p=0.0495	p=0.0402	p=0.0018

DLX5							
Day	2	4	6	8	10	12	14
	ALX1^{165F/165F}						
ALX1^{165L/165L}	p=0.000006	p=2e ⁻¹⁰	p=0.0134	p=3e ⁻¹²	p=2e ⁻¹⁴	p=1e ⁻¹⁵	p=1e ⁻¹⁵
ALX1^{165L/165F}	p=0.00004	p=0.000003	p=0.0018	p=0.0027	p=0.00001	p=0.0037	p=0.000002

FOXD3							
Day	2	4	6	8	10	12	14
	ALX1^{165F/165F}						
ALX1^{165L/165L}	NS	NS	NS	NS	NS	NS	NS
ALX1^{165L/165F}	NS	NS	NS	NS	NS	NS	NS

P75							
Day	2	4	6	8	10	12	14
	ALX1^{165F/165F}						
ALX1^{165L/165L}	NS	NS	NS	NS	NS	NS	NS
ALX1^{165L/165F}	NS	NS	NS	NS	NS	NS	NS

TFAP2A							
Day	2	4	6	8	10	12	14
	ALX1^{165F/165F}						
ALX1^{165L/165L}	p=0.00004	p=1e ⁻¹⁵	p=1e ⁻¹⁵	p=9e ⁻¹⁵	p=2e ⁻⁹	p=8e ⁻⁹	p=1e ⁻¹⁵
ALX1^{165L/165F}	p=0.00002	p=0.00003	p=0.00007	p=0.001	p=0.0335	p=0.0464	p=0.0008

SLUG							
Day	2	4	6	8	10	12	14
	ALX1^{165F/165F}						
ALX1^{165L/165L}	NS	$p=2e^{-13}$	$p=0.0217$	$p=0.00007$	$p=0.00001$	$p=0.0004$	$p=0.022$
ALX1^{165L/165F}	NS	$p=1e^{-15}$	$p=5e^{-7}$	$p=2e^{-10}$	$p=7e^{-10}$	$p=0.00001$	$p=0.000001$

HAND2							
Day	2	4	6	8	10	12	14
	ALX1^{165F/165F}						
ALX1^{165L/165L}	NS	NS	NS	NS	NS	NS	NS
ALX1^{165L/165F}	NS	NS	NS	NS	NS	NS	NS

***: Significant differences when comparing undifferentiated iPSC ($p < 0.05$), $ALX1^{165L/165L}$ and $ALX1^{165F/165F}$ iPSC ($p < 0.05$).

MSX2							
Day	2	4	6	8	10	12	14
	$ALX1^{165F/165F}$						
$ALX1^{165L/165L}$	p=0.00002	p=4e ⁻⁶	p=0.0144	p=5e ⁻⁷	p=1e ⁻⁷	p=9e ⁻⁸	p=0.00003

DLX5							
Day	2	4	6	8	10	12	14
	$ALX1^{165F/165F}$						
$ALX1^{165L/165L}$	p=0.0021	p=NS	p=0.00009	p=0.003	p=2e ⁻¹³	p=1e ⁻¹⁵	0,000002

TFAP2A							
Day	2	4	6	8	10	12	14
	$ALX1^{165F/165F}$						
$ALX1^{165L/165L}$	p=0.0035	p=0.00006	p=0.0005	p=0.0002	p=0.0018	p=0.0027	0.0008

Supplemental Table 2: P-values for Figure 6.

<i>alx1</i>					
Time	4 hpf	10ss	24hpf	36hpf	48hpf
	alx1-/-	alx1-/-	alx1-/-	alx1-/-	alx1-/-
1 cell	NS	NS	p=0.0000004	p=0.002	p=0.000003
	Wild Type	Wild Type	Wild Type	Wild Type	Wild Type
1 cell	p=0.00000002	p=0.0000002	p=0.000001	p=0.0000009	p=0.00000003

<i>alx3</i>					
Time	4 hpf	10ss	24hpf	36hpf	48hpf
	alx1-/-	alx1-/-	alx1-/-	alx1-/-	alx1-/-
1 cell	p=0.01	p=0.006	p=0.000001	p=0.000003	p=0.0000003
	Wild Type	Wild Type	Wild Type	Wild Type	Wild Type
1 cell	p=0.003	p=0.0007	p=0.000006	p=0.000004	p=0.0000001

<i>alx4a</i>					
Time	4 hpf	10ss	24hpf	36hpf	48hpf
	alx1-/-	alx1-/-	alx1-/-	alx1-/-	alx1-/-
1 cell	p=0.004	p=0.001	p=0.00007	p=0.0002	p=0.00005
	Wild Type	Wild Type	Wild Type	Wild Type	Wild Type
1 cell	p=0.005	p=0.0006	p=0.00004	p=0.0000002	p=0.000003

<i>alx4b</i>					
Time	4 hpf	10ss	24hpf	36hpf	48hpf
	alx1-/-	alx1-/-	alx1-/-	alx1-/-	alx1-/-
1 cell	NS	NS	p=0.003	p=0.0006	p=0.00000002
	Wild Type	Wild Type	Wild Type	Wild Type	Wild Type
1 cell	NS	NS	p=0.012	p=0.000006	p=0.000005

*: Significantly different from WT zebrafish

<i>alx1</i>					
Time	4 hpf	10ss	24hpf	36hpf	48hpf
	alx1 ^{-/-}	alx1 ^{-/-}	alx1 ^{-/-}	alx1 ^{-/-}	alx1 ^{-/-}
Wild type	p=0.0043	p=0.117	p=0.0000028	p=3e ⁻⁸	p=0.0179

<i>alx3</i>					
Time	4 hpf	10ss	24hpf	36hpf	48hpf
	alx1 ^{-/-}	alx1 ^{-/-}	alx1 ^{-/-}	alx1 ^{-/-}	alx1 ^{-/-}
Wild type	NS	p=0.0055	p=3e ⁻¹⁰	p=4e ⁻⁹	p=0.0017

<i>alx4a</i>					
Time	4 hpf	10ss	24hpf	36hpf	48hpf
	alx1 ^{-/-}	alx1 ^{-/-}	alx1 ^{-/-}	alx1 ^{-/-}	alx1 ^{-/-}
Wild type	NS	NS	p=2e ⁻⁹	p=2e ⁻⁸	NS

<i>alx4b</i>					
Time	4 hpf	10ss	24hpf	36hpf	48hpf
	alx1 ^{-/-}	alx1 ^{-/-}	alx1 ^{-/-}	alx1 ^{-/-}	alx1 ^{-/-}
Wild type	NS	NS	NS	NS	NS

Supplemental Table 3: Primers used for qPCR (human genes)

Gene Name	Forward Primer	Reverse Primer
<i>GAPDH</i>	GACAGTCAGCCGCATCTTCT	TTAAAAGCAGCCCTGGTGAC
<i>RPLP0</i>	CAGATCCGCATGTCCCTTCG	AACACAAAGCCCACATTCCC
<i>OCT4</i>	TGGAGTTTGTGCCAGGGTTT	CTGTGTCCCAGGCTTCTTT
<i>NANOG</i>	GTCCCAAAGGCAAACAACCC	GCTGGGTGGAAGAGAACACA
<i>AFP</i>	CATATGCCAACAGGAGGCCA	CTGAGCTTGGCACAGATCCT
<i>GATA4</i>	GAAGGAGCCAGCCTAGCAG	CTATTGGGGGCAGAAGACGG
<i>FOXA2</i>	GCACTCGGCTTCCAGTATGC	TGTTTATGCCGTTTCATCCCC
<i>BRACHYURY</i>	GCTCTGCCCCCTAGAATGTG	ACAAAAGGAGGGGCTTCAC
<i>RUNX1</i>	GGAAGTCAACCTCTGCTGCT	TCGGACCACAGAGCACTTTC
<i>CD34</i>	TCTAGGCTCCAGCCAGAAAA	AAAACGTGTTGCCTTGAACC
<i>NESTIN</i>	GTAGCTCCCAGAGAGGGGAA	CTGTCCTGGGACTCCGTTTC
<i>GFAP</i>	CAGAGCCTCAAGGACGAGAT	GCTTTTGCCCCCTCGAATC
<i>SOX1</i>	CAACCAGGACCGGGTCAAAC	CCTCGGACATGACCTTCCAC
<i>ALX1</i>	CTGAGCGAGAAGTTTGCCCT	TGTCCAGCGTCTCCATAACG
<i>PAX3</i>	TCCATACGTCCTGGTGCCAT	TTCTCCACGTCAGGC GTTG
<i>ZIC1</i>	CGAGCGACAAGCCCTATCTT	TCTGTGGAGGGAGACACGAT
<i>TWIST1</i>	GCATTCTCAAGAGGTCGTGC	TTTGCAGGCCAGTTTGATCC
<i>TFAP2A</i>	GAGAACAGAACAGGCCGTGA	TGACTCAGTCCCATGAAGCG
<i>MSX2</i>	CTGGTGAAGCCCTTCGAGAC	AGGGCTCATATGTCTTGGCG
<i>DLX5</i>	AGAGACTTCACGACTCCCA	ACACTCCTGTCATCGCTCA
<i>P75</i>	CCTCATCCCTGTCTATTGCTCC	GTTGGCTCCTTGCTTGTCTGC
<i>FOXD3</i>	GGCAAGGGCAACTACTGGA	GGCTGTAAGCGCCGAAG
<i>PAX7</i>	GGATGTGGAGTCGGAACCTG	CTGGGTAGTGGGTCCTCTCA
<i>MSX1</i>	TCCGCAAACACAAGACGAAC	TACTGCTTCTGGCGGA ACTT
<i>SNAI2</i>	TGTCATACCACAACCAGAGA	CTTGGAGGAGGTGTCAGAT
<i>HAND2</i>	GACACTCCCGTGTGGTAAGG	AAGGGGTTGAGTAGGTTGGC

Supplemental Table 4: Primers used for qPCR (zebrafish genes)

Gene Name	Forward Primer	Reverse Primer
<i>elfa</i>	CTTCTCAGGCTGACTGTGC	CCGCTAGCATTACCCTCC
<i>18S</i>	TCGCTAGTTGGCATCGTTTATG	CGGAGGTTCGAAGACGATCA
<i>alx1</i>	CGTGACTTACTGCGCTCCTA	CGAGTTCGTCGAGGTCTGTT
<i>alx3</i>	TTATGGGACGCTACGCTGAC	AGTGTGTTTTCCAGGCGAGG
<i>alx4a</i>	CGAGTTGCCCAAACAGTG	ACGGTTGCGTCTTTTCTTGC
<i>alx4b</i>	ACTGGATGATAGCACAGCCG	ACCGTAGCATGAGATCAGCG
<i>pax3a</i>	ATACGACCGTGCGTCATCTC	ACGTCAGGAGTTGTGCTCTG
<i>pax3b</i>	CACAGAGGCACGAGTACAGG	TACGGGGACAGACTCGACAT

Figure Legend

Figure 1. Clinical presentation of the FND pedigree and generation of control, father, and subject-derived iPSC.

A. Pedigree family tree: includes two unaffected parents, 4 unaffected male siblings, 5 unaffected female siblings, and 2 each female and male affected siblings. Subjects 1-6, indicated in red, were enrolled in the study. Subjects 4-6 show complex FND with ocular involvement. The eldest affected sibling (subject 4) presented with right coloboma, left microphthalmia, and bilateral Tessier 4 oblique facial clefts. Subject 5 presented with bilateral anophthalmia with fused eyelids and shallow orbits, with bilateral oblique facial clefts. Subject 6 presented with bilateral anophthalmia with open shallow orbits, absent upper and lower eyelids, exposed orbital mucosa, bilateral oblique facial clefts, and malformed nasal ala with nodular skin tags. iPSC were generated using blood samples collected from subjects 1, 5, and 6.

B. Whole exome sequencing was carried out and analysis revealed a missense L165F variant (c.648C>T) in the *ALX1* homeodomain, heterozygous in the parents ($ALX1^{165L/165F}$), wildtype in the unaffected sibling ($ALX1^{165L/165L}$), and homozygous in both affected subjects ($ALX1^{165F/165F}$).

C. Schematic of the *ALX1* protein structure showing the position of the L165F substitution described here (red) and the locations of exon borders affected by two reported pathogenic variants (purple)(Ullah et al., 2016, Uz et al., 2010).

D. Schematic of the *ALX1* genomic sequence, showing the locations of the three reported pathogenic variants. The purple bar at the bottom represents a FND-associated homozygous *ALX1* deletion previously reported in the literature (Ullah et al., 2016, Uz et al., 2010).

E. Immunofluorescence staining for pluripotent markers *SSEA4*, *OCT4*, *SOX2*, and *TRA-1-60* and alkaline phosphatase staining of iPSC clones. One representative iPSC clone is shown for each genotype. Scale bar: 400 μ m.

F. Expression of pluripotent (*OCT4*, *NANOG*), endoderm (Endo., *AFP*, *GATA4*, *FOXA2*), ectoderm (Ecto., *NESTIN*, *GFAP*, *SOX1*), and mesoderm (Meso., *BRACH. (BRACHYURY)*, *RUNX1*, *CD34*) gene markers for $ALX1^{165L/165L}$ (green), $ALX1^{165L/165F}$ (red), and $ALX1^{165F/165F}$ (blue) iPSC relative to undifferentiated cells (UND). Data are represented as pooled mean \pm SEM of three experiments on three clones from each genotype.

Significance: $p=0.0167$ for *OCT4*, $p=0.0005$ for *NANOG*, $p=0.000004$ for *AFP*, $p=0.0082$ for *GATA4*, $p=0.0137$ for *FOXA2*, $p=0.00002$ for *NESTIN*, $p=0.0167$ for *GFAP*, $p=0.0014$ for *SOX1*, $p=0.0117$ for *BRACHYURY*, $p=0.0008$ for *RUNX1* and $p=0.0068$ for *CD34* when comparing undifferentiated and differentiated $ALX1^{165L/165L}$ iPSC.

p=0.0013 for OCT4, p=0.0011 for NANOG, p=0.0000003 for AFP, p=0.0003 for GATA4, p=0.0063 for FOXA2, p=0.0001 for NESTIN, p=0.027 for GFAP, p =0.000002 for SOX1, p=0.000009 for BRACHYURY, p=3e⁻⁹ for RUNX1 and p=0.000006 for CD34 when comparing undifferentiated and differentiated *ALX1*^{165F/165L} iPSC.

p=0.0201 for OCT4, p=0.006 for NANOG, p=1x10⁻¹² for AFP, p=5x10⁻¹³ for GATA4, p=0.0031 for FOXA2, p=0.0292 for NESTIN, p=0.00001 for GFAP, p=6x10⁻⁷ for SOX1, p=0.0204 for BRACHYURY, p=0.0009 for RUNX1 and p=0.000003 for CD34 when comparing undifferentiated and differentiated *ALX1*^{165F/165F} iPSC.

Figure 2: Generation of iPSC-derived NCC.

A. Schematic of the differentiation protocol timeline. Maintenance Medium (MM) = iPSC medium (StemFlex with 1x penicillin/streptomycin), NCC differentiation medium = DMEM-F12, 10% fetal bovine serum, 1 mM sodium pyruvate, 1 mM penicillin/streptomycin, 1 mM non-essential amino acids, 110 μM 2-mercaptoethanol, 10 ng/mL epidermal growth factor.
B. Images of iPSC and iPSC-derived NCC at Days 0, 14, and passage 4 following differentiation. Scale bars: 400 μm (Day 0), 200μm (Day 14, passage 4).

Figure 3: Timeline of key NCC-associated genes during differentiation.

Gene expression analysis across NCC differentiation of unaffected control *ALX1*^{165L/165L} (green), heterozygous *ALX1*^{165L/165F} (magenta) and homozygous *ALX1*^{165F/165F} iPSC: *ALX1*, neural plate border specifier genes *ZIC1*, *PAX7*, *PAX3*, *MSX1*, *MSX2*, *DLX5*; neural crest specifier genes *FOXD3*, *P75*, *TFAP2A*, *SNAI2*, *TWIST1*; and lineage specifier gene *HAND2*. The RT-qPCR relative expression values were normalized to *RPLP0* and *GAPDH* expression. Data is represented as pooled mean ± SEM of three experiments on three clones from each genotype. Statistical significance denoted by *: refer to supplemental table 1 for p-values.

Figure 4: NCC apoptosis, cell cycle and differentiation.

A. Homozygous *ALX1*^{165F/165F} NCC (blue) showed an increase in sensitivity to apoptosis when compared to control *ALX1*^{165L/165L} NCC (black). The data on the left represents the mean percentage of Annexin V positive cells, indicative of apoptosis, as determined by FACS analysis, with the data on the right being an example of one such experiment. Apoptosis was induced by immersion in a 55°C water bath for ten minutes. Representative experiment for each condition is shown. Data is represented as pooled mean ± SEM of three independent experiments.

*: Significantly different from the basal apoptosis rate: $p=3 \times 10^{-12}$ between control NCC basal apoptosis and induced apoptosis, and between $ALX1^{165F/165F}$ NCC basal apoptosis and induced apoptosis.

** : Significantly different from control NCC ($p=0.0004$).

B. Expression levels of cyclins *CCNA2* (blue) and *CCND1* (orange) in NCC at passages 2 and 3 of $ALX1^{165L/165L}$ and $ALX1^{165F/165F}$ NCC. The RT-qPCR relative expression values were normalized to *RPLP0* and *GAPDH* expression. Data is represented as pooled mean \pm SEM of three experiments on three clones from each genotype

*: Significantly different from control NCC at passage 2 ($p=0.001$ between control and $ALX1^{165F/165F}$ NCC at passage 2 for *CCNA2*, $p=0.0052$ for *CCND1*).

** : Significantly different from control NCC at passage 3 ($p=0.0494$ between control and $ALX1^{165F/165F}$ NCC for *CCNA2*, $p=0.0008$ for *CCND1*).

C. Fluorescence Activated Cell Sorting (FACS) experiments showed that control $ALX1^{165L/165L}$ NCC (green) exhibited increased expression of mesenchymal markers CD90, CD105, and CD73 with culture time (passages 1 through 4), whereas homozygous $ALX1^{165F/165F}$ NCC (blue) showed a consistent expression of the markers expressed at passage 1 throughout. Further, control $ALX1^{165L/165L}$ NCC showed a downregulation of CD57 expression with culture time, while $ALX1^{165F/165F}$ NCC maintained the same level of CD57 across passages. Data are presented as the mean percentage of positive cells across passage numbers.

*: Significantly different from control NCC. For CD90, $p=0.0013$ at passage 3 and $p=0.0207$ at passage 4. For CD105, $p=0.0016$ at passage 2, $p=0.00004$ at passage 3 and $p=0.0021$ at passage 4. For CD73, $p=0.0060$ at passage 2, $p=0.00004$ at passage 3 and $p=0.0114$ at passage 4. For CD57, $p=0.0026$ at passage 2, $p=0.000003$ at passage 3 and $p=0.000007$ at passage 4.

Figure 5: $ALX1^{165F/165F}$ NCC show a migration defect and a difference in BMP secretion.

A. Mutant $ALX1^{165F/165F}$ NCC (blue) exhibited a migration defect in timed coverage of the central clearing of the wound assay when compared with control $ALX1^{165L/165L}$ NCC (black). Data is presented as percent area recovery of the central circular clear area of the wound assay by migrating NCC at the end of a 24-hour period. For fluorescent pictures, cells were stained in serum free media containing 3.6 μ M CellTracker Green CMFDA (Life Technologies) for 30 min at 37°C and allowed to recover for 30 min before starting the experiment. Images were acquired every 6 hours using a Keyence BZ-X800 microscope. Surface area analyses and percentages of coverage were measured using ImageJ software (NIH). The NCC were monitored over 24 hours. The data are represented as the average of the percentage of closure \pm SEM. Scale bar = 200 μ m.

*: Significantly different from control NCC ($p<0.0001$).

B. Multiplex analysis of BMP2 and BMP9 in the supernatant of cultured NCC showed that *ALX1*^{165F/165F} NCC (blue) secrete less BMP2 and more BMP9 compared to control *ALX1*^{165L/165L} NCC (green). Data are represented as pooled mean \pm SEM of three clones from each genotype.

*: Significantly different from control NCC ($p = 0.0424$ for BMP2 and $p = 0.0192$ for BMP9).

C. Addition of soluble BMP2 or CV2, a BMP9 antagonist, to the culture medium could partially rescue the migration defect of *ALX1*^{165F/165F} NCC. At the beginning of the assay, 100 ng/ml of soluble BMP2, CV2, or a combination of the two were added to the culture medium, and the cells were monitored over the next 24 hours. The data are represented as the average of the percentage of closure \pm SEM. Scale bar: 400 μ m.

Figure 6: *alx1* function in Zebrafish.

A. Dissected flatmount wild type and *alx1*^{-/-} zebrafish larvae craniofacial cartilages after Alcian blue staining, the anterior points to the left of the page in all images. The ventral cartilages appear normal, but the *alx1*^{-/-} anterior neurocranium (ANC) appears narrow, with the midline element that is derived from the frontonasal NCC being absent. The Meckel's cartilage (arrow, MC) is also diminutive. Scale bar: 200 μ m.

B. Zebrafish *alx1* mutants (blue) show reduced detectable expression of *alx1* but increased expression of *alx3*, *alx4a* compared to wild type controls (green). *alx4b* expression levels are similar between wild type and *alx1*^{-/-} lines. Data is represented as the mean of all pooled embryos. The RT-qPCR relative expression values were normalized to *elfa* and *18S* expression using the $\Delta\Delta$ CT method. Statistical significance denoted by *; $p < 0.0001$ between WT zebrafish and *alx1*^{-/-} at all measured time points; at 10ss, 24hpf and 36hpf for *alx3*; and at 24hpf and 36hpf for *alx4a*. Refer to supplemental table 2 for p-values.

C. Dissected flatmount of zebrafish embryos injected with Alx1DN, after Alcian blue staining. The embryos developed an absence of the frontonasal derived median portion of the anterior neurocranium (ANC) and a profound hypoplasia of the Meckel's and ventral cartilages. In the most severely affected zebrafish, a nearly abrogated ANC was observed. Scale bar: 200 μ m.

D. Lineage tracing experiments in control and Alx1DN mutant embryos revealed aberrant migration of anterior cranial NCC when *alx1* is disrupted. In the control animal, the anterior cranial NCC always migrate to contribute to the median portion of the ANC. In contrast, the anterior cranial NCC labeled in the Alx1DN animals fail to migrate to the median ANC, where the ANC structure is narrower and the labeled cranial NCC are found in an anterior and lateral ectopic location (white asterisks).

Supplemental Figure Legend

Supplemental Figure 1. iPSC derivation and EB generation.

A. Schematic representation of the strategy used to generate iPSC. Blood samples from an unrelated normal individual, unaffected father (subject 1) and two of the affected children (subjects 5 and 6) were processed. Isolated PBMC were infected with Sendai virus and individual clones were picked 21 days after the infection. Following expansion until passage 10, iPSC were characterized and embryoid bodies were formed by suspension culture for 14 days.

B. The reprogramming process of the PBMC showed that all cells underwent similar morphological changes leading to the formation of iPSC clones by day 21. These clones still displayed embryonic stem cells morphology at passage 10, indicating that the cells are able to self-renew. All iPSC clones were able to form EBs. One clone of each subject is represented. Scale bar is 400 μm .

Supplemental Figure 2. Characterization of NCC.

Multilineage differentiation experiments revealed that both control and subject-derived NCC are able to differentiate into Schwann cells, shown by the GFAP and S100B positive immunofluorescence staining; adipocytes, demonstrated by the Oil Red O. positive lipidic droplets; osteoblasts, shown by Alizarin Red S. positive mineralized nodules and chondrocytes, assessed by Alcian Blue-positive cartilaginous matrix. Scale bar is 200 μm for images of Schwann cells and adipocytes, and 400 μm for images of chondrocytes and osteoblasts.

Supplemental Figure 3. Effect of BMP2 and CV2 on NCC migration.

A. For fluorescent pictures, cells were stained in serum free media containing 3.6 μM CellTracker Green CMFDA (Life Technologies) for 30 min at 37°C and allowed to recover for 30 min before starting the experiment. 10 or 50 ng/ml of soluble BMP2 was added to the culture medium. Images were captured at 0 and 24 hours with a Keyence BZ-X800 microscope. Surface area analyses and percentages of coverage were measured using ImageJ software (NIH). The data of NCC migration following the treatment with 10, 50, 100 ng/ml soluble BMP2 are represented as the average of the percentage of closure \pm SEM. Scale bar = 400 μm .

*: Significantly different from untreated $ALX1^{165F/165F}$ NCC: at 12 hours, $p=0.0038$ when comparing BMP2 50ng/ml- and untreated $ALX1^{165F/165F}$ NCC, and $p=0.0045$ when comparing BMP2 100ng/ml- and untreated $ALX1^{165F/165F}$ NCC. At 18 hours, $p=0.0337$ when comparing BMP2 10ng/ml- and untreated $ALX1^{165F/165F}$ NCC; $p=0.0009$ when comparing BMP2 50ng/ml- and untreated $ALX1^{165F/165F}$ NCC; and $p=0.0006$ when comparing BMP2 100ng/ml- and

untreated $ALX1^{165F/165F}$ NCC. At 24 hours, $p = 0.005$ when comparing BMP2 10ng/ml- and untreated $ALX1^{165F/165F}$ NCC; $p < 0$. when comparing BMP2 50ng/ml- and untreated $ALX1^{165F/165F}$ NCC; and $p < 0.0001$ when comparing BMP2 100ng/ml- and untreated $ALX1^{165F/165F}$ NCC.

B. For fluorescent pictures, cells were stained in serum free media containing 3.6 μ M CellTracker Green CMFDA (Life Technologies) for 30 min at 37°C and allowed to recover for 30 min before starting the experiment. 10 or 50 ng/ml of soluble CV2 was added to the culture medium. Images were captured at 0 and 24 hours with a Keyence BZ-X800 microscope. Surface area analyses and percentages of coverage were measured using ImageJ software (NIH). The data of NCC migration following the treatment with 10, 50, 100 ng/ml soluble CV2 are represented as the average of the percentage of closure \pm SEM. Scale bar = 400 μ m.

*: Significantly different from untreated $ALX1^{165F/165F}$ NCC: A=at 12 hours, $p = 0.0146$ when comparing CV2 50ng/ml- and untreated $ALX1^{165F/165F}$ NCC, and $p = 0.0262$ when comparing CV2 100ng/ml- and untreated $ALX1^{165F/165F}$ NCC. At 18 hours, $p = 0.0028$ when comparing CV2 50ng/ml- and untreated $ALX1^{165F/165F}$ NCC, and $p = 0.0035$ when comparing CV2 100ng/ml- and untreated $ALX1^{165F/165F}$ NCC. At 24 hours, $p = 0.0002$ when comparing CV2 50ng/ml- and untreated $ALX1^{165F/165F}$ NCC, and $p < 0.0001$ when comparing CV2 100ng/ml- and untreated $ALX1^{165F/165F}$ NCC.

C. Recovery of subject-derived NCC migration in a migration assay following the combined treatment with 100 ng/ml each of soluble BMP2 and CV2. The data are represented as the average of the percentage of closure \pm SEM.

*: Significantly different from $ALX1^{165F/165F}$ NCC: at 12 hours, $p = 0.0031$, at 18 hours $p = 0.0001$, and at 24 hours $p < 0.0001$).

Supplemental Figure 4. CRISPR/Cas9 targeted mutagenesis of *alx1* in zebrafish.





A. Human ALX1 and zebrafish *alx1* protein sequences were obtained from Ensembl and aligned using Clustal Omega (<https://www.ebi.ac.uk/Tools/msa/clustalo/>) under the default settings. The homeobox DNA binding domain is shown in bold, with the amino acid residue mutated in the subjects indicated by an outline. The transactivation domain is shaded in grey. Potential zebrafish *alx1* CRISPR sites #1 and #2 are highlighted in yellow.



B. Schematic diagram shows the effect of the mutant allele resulting from our choice of target site #1. The allele, termed, $alx1^{uw2016}$, has a net deletion of 16 nucleotides. Red letters denote the abnormal sequence that results from the frame shift mutation.

Supplemental Figure 5. Qualitative and quantitative characterization of zebrafish mutants.

A. The number of embryos displaying craniofacial phenotypes increased with increasing concentration of Alx1DN mRNA injected into the single cell stage embryo. Overview of the relationship of the results of injections of 25, 50, and 100 pg of control mRNA and Alx1DN mRNA with the outcomes of wildtype zebrafish (green), a craniofacial phenotype (gray), and dead zebrafish (magenta).


B. The number of embryos displaying craniofacial phenotypes injected with *alx1^{uw2016}* mRNA was very low. Overview of the percent of injected wildtype zebrafish displaying a craniofacial phenotype (gray), compared with uninjected wildtype zebrafish from the identical clutches (gray). Data of the injections is presented as a comparative percentage.








Neural Plate Neuron Specifier







Neural Crest Specifier









Trigeminal Specifier









A**B**

Control NCC

ALX1^{Cre/loxP} NCC

Schwann cells



Adipocytes






Chondrocytes




Osteoblasts





A**B**

A**B**